AHCO

SEC source: 0001104659-20-133876 · tm2038090-3_4seq1.xml · nonDerivative · entry 3

Rietkerk Shaw · CIK 0001792695 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 200,224

F3 · price: This transaction was executed in multiple trades at prices ranging from $34.86 to $35.23. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001104659-20-133876 · tm2038090-3_4seq1.xml · nonDerivative · entry 2

Rietkerk Shaw · CIK 0001792695 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 212,224

F2 · shares: Represents the number of shares of Class A Common Stock otherwise issuable upon the exchange of shares of Class B Common Stock of the Issuer (together with the same number of common units of AdaptHealth Holdings LLC) with respect to which the Issuer elected to deliver cash in lieu of shares of Class A Common Stock pursuant to the terms of the Exchange Agreement.

SEC source: 0001104659-20-133876 · tm2038090-3_4seq1.xml · nonDerivative · entry 1

Rietkerk Shaw · CIK 0001792695 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 257,224

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Represents shares of Class A Common Stock of the Issuer issued upon an exchange of an equivalent number of shares of Class B Common Stock of the Issuer pursuant to the terms of that certain Exchange Agreement, dated as of November 8, 2019 (the "Exchange Agreement"), by and among the Issuer, AdaptHealth Holdings LLC and the other parties thereto (together with the same number of common units of AdaptHealth Holdings LLC).

SEC source: 0001104659-20-133875 · tm2038090-2_4seq1.xml · derivative · entry 9

McGee Luke · CIK 0001792721 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Class A Common Stock · 1,081,249 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · derivative.exercise_price: The Class B Common Stock is exchangeable (together with the same number of common units of AdaptHealth Holdings LLC) for shares of Class A Common Stock of the Issuer (or the cash value thereof). 319,724 of the common units of AdaptHealth Holdings LLC held directly by 2321 Capital LLC are subject to vesting, with 79,931 units vesting on each of the first four anniversaries of May 20, 2019.

F7 · price: The Class B Common Stock is exchangeable (together with the same number of common units of AdaptHealth Holdings LLC) for shares of Class A Common Stock of the Issuer (or the cash value thereof). 319,724 of the common units of AdaptHealth Holdings LLC held directly by 2321 Capital LLC are subject to vesting, with 79,931 units vesting on each of the first four anniversaries of May 20, 2019.

F7 · derivative.exercise_date: The Class B Common Stock is exchangeable (together with the same number of common units of AdaptHealth Holdings LLC) for shares of Class A Common Stock of the Issuer (or the cash value thereof). 319,724 of the common units of AdaptHealth Holdings LLC held directly by 2321 Capital LLC are subject to vesting, with 79,931 units vesting on each of the first four anniversaries of May 20, 2019.

F7 · derivative.expiration_date: The Class B Common Stock is exchangeable (together with the same number of common units of AdaptHealth Holdings LLC) for shares of Class A Common Stock of the Issuer (or the cash value thereof). 319,724 of the common units of AdaptHealth Holdings LLC held directly by 2321 Capital LLC are subject to vesting, with 79,931 units vesting on each of the first four anniversaries of May 20, 2019.

F6 · ownership.nature: Securities held directly by LBM DBE Holdings LLC.

SEC source: 0001104659-20-133875 · tm2038090-2_4seq1.xml · derivative · entry 8

McGee Luke · CIK 0001792721 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Class A Common Stock · 1,620,815 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · derivative.exercise_price: The Class B Common Stock is exchangeable (together with the same number of common units of AdaptHealth Holdings LLC) for shares of Class A Common Stock of the Issuer (or the cash value thereof). 319,724 of the common units of AdaptHealth Holdings LLC held directly by 2321 Capital LLC are subject to vesting, with 79,931 units vesting on each of the first four anniversaries of May 20, 2019.

F7 · price: The Class B Common Stock is exchangeable (together with the same number of common units of AdaptHealth Holdings LLC) for shares of Class A Common Stock of the Issuer (or the cash value thereof). 319,724 of the common units of AdaptHealth Holdings LLC held directly by 2321 Capital LLC are subject to vesting, with 79,931 units vesting on each of the first four anniversaries of May 20, 2019.

F7 · derivative.exercise_date: The Class B Common Stock is exchangeable (together with the same number of common units of AdaptHealth Holdings LLC) for shares of Class A Common Stock of the Issuer (or the cash value thereof). 319,724 of the common units of AdaptHealth Holdings LLC held directly by 2321 Capital LLC are subject to vesting, with 79,931 units vesting on each of the first four anniversaries of May 20, 2019.

F7 · derivative.expiration_date: The Class B Common Stock is exchangeable (together with the same number of common units of AdaptHealth Holdings LLC) for shares of Class A Common Stock of the Issuer (or the cash value thereof). 319,724 of the common units of AdaptHealth Holdings LLC held directly by 2321 Capital LLC are subject to vesting, with 79,931 units vesting on each of the first four anniversaries of May 20, 2019.

F5 · ownership.nature: Securities held directly by Fresh Pond Investment LLC.

SEC source: 0001104659-20-133875 · tm2038090-2_4seq1.xml · derivative · entry 7

McGee Luke · CIK 0001792721 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 389,793

Underlying: Class A Common Stock · 1,434,171 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · derivative.exercise_price: The Class B Common Stock is exchangeable (together with the same number of common units of AdaptHealth Holdings LLC) for shares of Class A Common Stock of the Issuer (or the cash value thereof). 319,724 of the common units of AdaptHealth Holdings LLC held directly by 2321 Capital LLC are subject to vesting, with 79,931 units vesting on each of the first four anniversaries of May 20, 2019.

F7 · price: The Class B Common Stock is exchangeable (together with the same number of common units of AdaptHealth Holdings LLC) for shares of Class A Common Stock of the Issuer (or the cash value thereof). 319,724 of the common units of AdaptHealth Holdings LLC held directly by 2321 Capital LLC are subject to vesting, with 79,931 units vesting on each of the first four anniversaries of May 20, 2019.

F7 · derivative.exercise_date: The Class B Common Stock is exchangeable (together with the same number of common units of AdaptHealth Holdings LLC) for shares of Class A Common Stock of the Issuer (or the cash value thereof). 319,724 of the common units of AdaptHealth Holdings LLC held directly by 2321 Capital LLC are subject to vesting, with 79,931 units vesting on each of the first four anniversaries of May 20, 2019.

F7 · derivative.expiration_date: The Class B Common Stock is exchangeable (together with the same number of common units of AdaptHealth Holdings LLC) for shares of Class A Common Stock of the Issuer (or the cash value thereof). 319,724 of the common units of AdaptHealth Holdings LLC held directly by 2321 Capital LLC are subject to vesting, with 79,931 units vesting on each of the first four anniversaries of May 20, 2019.

F4 · ownership.nature: Securities held directly by 2321 Capital LLC.

SEC source: 0001104659-20-133875 · tm2038090-2_4seq1.xml · nonDerivative · entry 5

McGee Luke · CIK 0001792721 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 1,168,800

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: Represents shares of Class A Common Stock of the Issuer issued upon an exchange of an equivalent number of shares of Class B Common Stock of the Issuer pursuant to the terms of that certain Exchange Agreement, dated as of November 8, 2019 (the "Exchange Agreement"), by and among the Issuer, AdaptHealth Holdings LLC and the other parties thereto (together with the same number of common units of AdaptHealth Holdings LLC).

F6 · ownership.nature: Securities held directly by LBM DBE Holdings LLC.

SEC source: 0001104659-20-133875 · tm2038090-2_4seq1.xml · nonDerivative · entry 4

McGee Luke · CIK 0001792721 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 1,752,056

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: Represents shares of Class A Common Stock of the Issuer issued upon an exchange of an equivalent number of shares of Class B Common Stock of the Issuer pursuant to the terms of that certain Exchange Agreement, dated as of November 8, 2019 (the "Exchange Agreement"), by and among the Issuer, AdaptHealth Holdings LLC and the other parties thereto (together with the same number of common units of AdaptHealth Holdings LLC).

F5 · ownership.nature: Securities held directly by Fresh Pond Investment LLC.

SEC source: 0001104659-20-133875 · tm2038090-2_4seq1.xml · nonDerivative · entry 3

McGee Luke · CIK 0001792721 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 277,151

F3 · shares: Represents the number of shares of Class A Common Stock otherwise issuable upon the exchange of shares of Class B Common Stock of the Issuer (together with the same number of common units of AdaptHealth Holdings LLC) with respect to which the Issuer elected to deliver cash in lieu of shares of Class A Common Stock pursuant to the terms of the Exchange Agreement.

F4 · ownership.nature: Securities held directly by 2321 Capital LLC.

SEC source: 0001104659-20-133875 · tm2038090-2_4seq1.xml · nonDerivative · entry 2

McGee Luke · CIK 0001792721 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 1,589,959

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: Represents shares of Class A Common Stock of the Issuer issued upon an exchange of an equivalent number of shares of Class B Common Stock of the Issuer pursuant to the terms of that certain Exchange Agreement, dated as of November 8, 2019 (the "Exchange Agreement"), by and among the Issuer, AdaptHealth Holdings LLC and the other parties thereto (together with the same number of common units of AdaptHealth Holdings LLC).

F4 · ownership.nature: Securities held directly by 2321 Capital LLC.

SEC source: 0000899243-20-031644 · doc4.xml · nonDerivative · entry 1

Assured Investment Management LLC · CIK 0001427430 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Footnotes

Disclosed balance after: 1,915,934

F1 · security: The filing of this Form 4 shall not be construed as an admission that Assured Investment Management LLC (f/k/a BlueMountain Capital Management, LLC) ("AssuredIM") is or was for the purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise the beneficial owner of any shares of Class A Common Stock, par value $0.0001 per share ("Class A Common Stock"), of AdaptHealth Corp. (the "Issuer"). Pursuant to Rule 16a-1(a)(4) of the Exchange Act, AssuredIM disclaims such beneficial ownership, except to the extent of its pecuniary interest.

F2 · security: AssuredIM is the investment manager of each of: (i) BMSB L.P. ("BMSB"); (ii) BlueMountain Fursan Fund L.P. ("FRSN"); (iii) BlueMountain Foinaven Master Fund L.P. ("BMFV"); and (iv) BlueMountain Summit Opportunities Fund II (US) L.P. Fund L.P. ( "BMSO" and, together with BMSB, FRSN and BMFV, the "Funds"), which are the direct beneficial owners of 1,915,934 shares of Class A Common Stock in the aggregate. AssuredIM, although it directs the disposition and voting of the Class A Common Stock held by the Funds, only receives an asset-based fee relating to the Class A Common Stock held by the Funds.

F3 · security: On November 17, 2020, BMSB, FRSN, BMFV and BMSO sold 1,048,533, 417,619, 341,230 and 74,618 shares of Class A Common Stock, respectively, for $27.95 per share.

F1 · ownership.nature: The filing of this Form 4 shall not be construed as an admission that Assured Investment Management LLC (f/k/a BlueMountain Capital Management, LLC) ("AssuredIM") is or was for the purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise the beneficial owner of any shares of Class A Common Stock, par value $0.0001 per share ("Class A Common Stock"), of AdaptHealth Corp. (the "Issuer"). Pursuant to Rule 16a-1(a)(4) of the Exchange Act, AssuredIM disclaims such beneficial ownership, except to the extent of its pecuniary interest.

F2 · ownership.nature: AssuredIM is the investment manager of each of: (i) BMSB L.P. ("BMSB"); (ii) BlueMountain Fursan Fund L.P. ("FRSN"); (iii) BlueMountain Foinaven Master Fund L.P. ("BMFV"); and (iv) BlueMountain Summit Opportunities Fund II (US) L.P. Fund L.P. ( "BMSO" and, together with BMSB, FRSN and BMFV, the "Funds"), which are the direct beneficial owners of 1,915,934 shares of Class A Common Stock in the aggregate. AssuredIM, although it directs the disposition and voting of the Class A Common Stock held by the Funds, only receives an asset-based fee relating to the Class A Common Stock held by the Funds.

SEC source: 0000899243-20-030983 · doc4.xml · nonDerivative · entry 1

Assured Investment Management LLC · CIK 0001427430 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Footnotes

Disclosed balance after: 3,797,934

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The filing of this Form 4 shall not be construed as an admission that Assured Investment Management LLC (f/k/a BlueMountain Capital Management, LLC) ("AssuredIM") is or was for the purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise the beneficial owner of any shares of Class A Common Stock, par value $0.0001 per share ("Class A Common Stock"), of AdaptHealth Corp. (the "Issuer") or Class B Common Stock, par value $0.0001 per share ("Class B Common Stock" and, together with the Class A Common Stock, the "Common Stock"), of the Issuer. Pursuant to Rule 16a-1(a)(4) of the Exchange Act, AssuredIM disclaims such beneficial ownership, except to the extent of its pecuniary interest.

F2 · security: AssuredIM is the investment manager of BlueMountain Summit Opportunities Fund II (US) L.P. (the "Fund"), which was the direct beneficial owner of 150,581 shares of Class B Common Stock and is the beneficial owner of 150,581 shares of Class A Common Stock. AssuredIM, although it directs the disposition and voting of the Common Stock held by the Fund, only receives an asset-based fee relating to the Common Stock.

F3 · security: Pursuant to the terms of the Exchange Agreement dated as of November 8, 2019 by and among the Issuer, AdaptHealth Holdings LLC, a subsidiary of the Issuer, and the other parties thereto (the "Exchange Agreement"), each share of Class B Common Stock, when combined with a common unit representing limited liability company interests in AdaptHealth Holdings LLC ("LLC Unit"), is exchangeable at any time for one share of Class A Common Stock or, at the Issuer's election, the cash equivalent to the market value of one share of Class A Common Stock. The Class B Common Stock has no expiration date.

F4 · security: On November 11, 2020, the Fund delivered notice to the Issuer for the conversion of 150,581 shares of Class B Common Stock and LLC Units pursuant to the terms of the Exchange Agreement. On November 12, 2020, in connection with such conversion, the Fund received 150,581 shares of Class A Common Stock from the Issuer.

F3 · price: Pursuant to the terms of the Exchange Agreement dated as of November 8, 2019 by and among the Issuer, AdaptHealth Holdings LLC, a subsidiary of the Issuer, and the other parties thereto (the "Exchange Agreement"), each share of Class B Common Stock, when combined with a common unit representing limited liability company interests in AdaptHealth Holdings LLC ("LLC Unit"), is exchangeable at any time for one share of Class A Common Stock or, at the Issuer's election, the cash equivalent to the market value of one share of Class A Common Stock. The Class B Common Stock has no expiration date.

F4 · price: On November 11, 2020, the Fund delivered notice to the Issuer for the conversion of 150,581 shares of Class B Common Stock and LLC Units pursuant to the terms of the Exchange Agreement. On November 12, 2020, in connection with such conversion, the Fund received 150,581 shares of Class A Common Stock from the Issuer.

F1 · ownership.nature: The filing of this Form 4 shall not be construed as an admission that Assured Investment Management LLC (f/k/a BlueMountain Capital Management, LLC) ("AssuredIM") is or was for the purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise the beneficial owner of any shares of Class A Common Stock, par value $0.0001 per share ("Class A Common Stock"), of AdaptHealth Corp. (the "Issuer") or Class B Common Stock, par value $0.0001 per share ("Class B Common Stock" and, together with the Class A Common Stock, the "Common Stock"), of the Issuer. Pursuant to Rule 16a-1(a)(4) of the Exchange Act, AssuredIM disclaims such beneficial ownership, except to the extent of its pecuniary interest.

F2 · ownership.nature: AssuredIM is the investment manager of BlueMountain Summit Opportunities Fund II (US) L.P. (the "Fund"), which was the direct beneficial owner of 150,581 shares of Class B Common Stock and is the beneficial owner of 150,581 shares of Class A Common Stock. AssuredIM, although it directs the disposition and voting of the Common Stock held by the Fund, only receives an asset-based fee relating to the Common Stock.

F3 · ownership.nature: Pursuant to the terms of the Exchange Agreement dated as of November 8, 2019 by and among the Issuer, AdaptHealth Holdings LLC, a subsidiary of the Issuer, and the other parties thereto (the "Exchange Agreement"), each share of Class B Common Stock, when combined with a common unit representing limited liability company interests in AdaptHealth Holdings LLC ("LLC Unit"), is exchangeable at any time for one share of Class A Common Stock or, at the Issuer's election, the cash equivalent to the market value of one share of Class A Common Stock. The Class B Common Stock has no expiration date.

SEC source: 0000899243-20-030983 · doc4.xml · derivative · entry 2

Assured Investment Management LLC · CIK 0001427430 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Footnotes

Disclosed balance after: 0

Underlying: Class A Common Stock · Not disclosed shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The filing of this Form 4 shall not be construed as an admission that Assured Investment Management LLC (f/k/a BlueMountain Capital Management, LLC) ("AssuredIM") is or was for the purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise the beneficial owner of any shares of Class A Common Stock, par value $0.0001 per share ("Class A Common Stock"), of AdaptHealth Corp. (the "Issuer") or Class B Common Stock, par value $0.0001 per share ("Class B Common Stock" and, together with the Class A Common Stock, the "Common Stock"), of the Issuer. Pursuant to Rule 16a-1(a)(4) of the Exchange Act, AssuredIM disclaims such beneficial ownership, except to the extent of its pecuniary interest.

F2 · security: AssuredIM is the investment manager of BlueMountain Summit Opportunities Fund II (US) L.P. (the "Fund"), which was the direct beneficial owner of 150,581 shares of Class B Common Stock and is the beneficial owner of 150,581 shares of Class A Common Stock. AssuredIM, although it directs the disposition and voting of the Common Stock held by the Fund, only receives an asset-based fee relating to the Common Stock.

F3 · security: Pursuant to the terms of the Exchange Agreement dated as of November 8, 2019 by and among the Issuer, AdaptHealth Holdings LLC, a subsidiary of the Issuer, and the other parties thereto (the "Exchange Agreement"), each share of Class B Common Stock, when combined with a common unit representing limited liability company interests in AdaptHealth Holdings LLC ("LLC Unit"), is exchangeable at any time for one share of Class A Common Stock or, at the Issuer's election, the cash equivalent to the market value of one share of Class A Common Stock. The Class B Common Stock has no expiration date.

F4 · security: On November 11, 2020, the Fund delivered notice to the Issuer for the conversion of 150,581 shares of Class B Common Stock and LLC Units pursuant to the terms of the Exchange Agreement. On November 12, 2020, in connection with such conversion, the Fund received 150,581 shares of Class A Common Stock from the Issuer.

F3 · derivative.exercise_price: Pursuant to the terms of the Exchange Agreement dated as of November 8, 2019 by and among the Issuer, AdaptHealth Holdings LLC, a subsidiary of the Issuer, and the other parties thereto (the "Exchange Agreement"), each share of Class B Common Stock, when combined with a common unit representing limited liability company interests in AdaptHealth Holdings LLC ("LLC Unit"), is exchangeable at any time for one share of Class A Common Stock or, at the Issuer's election, the cash equivalent to the market value of one share of Class A Common Stock. The Class B Common Stock has no expiration date.

F3 · derivative.expiration_date: Pursuant to the terms of the Exchange Agreement dated as of November 8, 2019 by and among the Issuer, AdaptHealth Holdings LLC, a subsidiary of the Issuer, and the other parties thereto (the "Exchange Agreement"), each share of Class B Common Stock, when combined with a common unit representing limited liability company interests in AdaptHealth Holdings LLC ("LLC Unit"), is exchangeable at any time for one share of Class A Common Stock or, at the Issuer's election, the cash equivalent to the market value of one share of Class A Common Stock. The Class B Common Stock has no expiration date.

F3 · derivative.underlying: Pursuant to the terms of the Exchange Agreement dated as of November 8, 2019 by and among the Issuer, AdaptHealth Holdings LLC, a subsidiary of the Issuer, and the other parties thereto (the "Exchange Agreement"), each share of Class B Common Stock, when combined with a common unit representing limited liability company interests in AdaptHealth Holdings LLC ("LLC Unit"), is exchangeable at any time for one share of Class A Common Stock or, at the Issuer's election, the cash equivalent to the market value of one share of Class A Common Stock. The Class B Common Stock has no expiration date.

F3 · derivative.underlying_shares: Pursuant to the terms of the Exchange Agreement dated as of November 8, 2019 by and among the Issuer, AdaptHealth Holdings LLC, a subsidiary of the Issuer, and the other parties thereto (the "Exchange Agreement"), each share of Class B Common Stock, when combined with a common unit representing limited liability company interests in AdaptHealth Holdings LLC ("LLC Unit"), is exchangeable at any time for one share of Class A Common Stock or, at the Issuer's election, the cash equivalent to the market value of one share of Class A Common Stock. The Class B Common Stock has no expiration date.

F1 · ownership.nature: The filing of this Form 4 shall not be construed as an admission that Assured Investment Management LLC (f/k/a BlueMountain Capital Management, LLC) ("AssuredIM") is or was for the purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise the beneficial owner of any shares of Class A Common Stock, par value $0.0001 per share ("Class A Common Stock"), of AdaptHealth Corp. (the "Issuer") or Class B Common Stock, par value $0.0001 per share ("Class B Common Stock" and, together with the Class A Common Stock, the "Common Stock"), of the Issuer. Pursuant to Rule 16a-1(a)(4) of the Exchange Act, AssuredIM disclaims such beneficial ownership, except to the extent of its pecuniary interest.

F2 · ownership.nature: AssuredIM is the investment manager of BlueMountain Summit Opportunities Fund II (US) L.P. (the "Fund"), which was the direct beneficial owner of 150,581 shares of Class B Common Stock and is the beneficial owner of 150,581 shares of Class A Common Stock. AssuredIM, although it directs the disposition and voting of the Common Stock held by the Fund, only receives an asset-based fee relating to the Common Stock.

F3 · ownership.nature: Pursuant to the terms of the Exchange Agreement dated as of November 8, 2019 by and among the Issuer, AdaptHealth Holdings LLC, a subsidiary of the Issuer, and the other parties thereto (the "Exchange Agreement"), each share of Class B Common Stock, when combined with a common unit representing limited liability company interests in AdaptHealth Holdings LLC ("LLC Unit"), is exchangeable at any time for one share of Class A Common Stock or, at the Issuer's election, the cash equivalent to the market value of one share of Class A Common Stock. The Class B Common Stock has no expiration date.

SEC source: 0000899243-20-028730 · doc4.xml · derivative · entry 4

Assured Investment Management LLC · CIK 0001427430 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Footnotes

Disclosed balance after: 1,898,967

Underlying: Class A and B Common Stock · 1,898,967 shares

Expires 2020-10-31

F1 · security: The filing of this Form 4 shall not be construed as an admission that Assured Investment Management LLC (f/k/a BlueMountain Capital Management, LLC) ("AssuredIM") is or was for the purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise the beneficial owner of any put options ("Put Options") relating to shares of Class A Common Stock, par value $0.0001 per share "Class A Common Stock") and Class B Common Stock, par value $0.0001 per share ("Class B Common Stock"), of AdaptHealth Corp. (the "Issuer"). Pursuant to Rule 16a-1(a)(4) of the Exchange Act, AssuredIM disclaims such beneficial ownership, except to the extent of its pecuniary interest.

F2 · security: AssuredIM is the investment manager of each of: (i) BMSB L.P. ("BMSB"); (ii) BlueMountain Fursan Fund L.P. ("FRSN"); (iii) BlueMountain Foinaven Master Fund L.P. ("BMFV"); and (iv) BlueMountain Summit Opportunities Fund II (US) L.P. (together with BMSB, FRSN and BMFV, the "Funds"), which collectively are the direct beneficial owners of 1,898,967 Put Options. AssuredIM, although it directs the exercise of the Put Options held by the Funds, only receives an asset-based fee relating to the Put Options held by the Funds.

F3 · security: In a Form 4 filed on May 27, 2020, the Funds reported that they entered into Put/Call Option and Consent Agreement (the "Option Agreement") dated as of May 25, 2020 with the Issuer pursuant to which the Funds acquired the Put Options from the Issuer and issued to the Issuer call options with respect to the Class A Common Stock and Class B Common Stock of the Issuer (the "Call Options"), each of which options expired on October 31, 2020. On October 16, 2020 the Issuer and the Funds entered into an Amendment to the Option Agreement (the "Amendment") that extended the expiration date of both the Put Options and the Call Options to December 31, 2020. The Amendment is reported in this Form 4 as (i) a cancellation of the original Put Options and Call Options and (ii) an issuance of replacement Put Options by the Issuer to the Funds and replacement Call Options by the Funds to the Issuer.

F4 · security: Pursuant to the Option Agreement, the Put Options may be exercised by the Funds at a per option price equal to the greater of (x) $14.50 and (y) 85% of the current market value of a share of Class A Common Stock on the date the Put Options are exercised, as determined in accordance with the terms of the Option Agreement.

F5 · security: Pursuant to the Option Agreement, both of the Put Options and the Call Options will become exercisable upon the closing date of a merger involving the Issuer, certain subsidiaries thereof, Solara Holdings, LLC and certain entities related thereto.

F6 · security: Pursuant to the Option Agreement, the Put Options and Call Options each relate to the shares of Class A Common Stock and Class B Common Stock held by the Funds, without distinguishing between such shares.

F3 · kind: In a Form 4 filed on May 27, 2020, the Funds reported that they entered into Put/Call Option and Consent Agreement (the "Option Agreement") dated as of May 25, 2020 with the Issuer pursuant to which the Funds acquired the Put Options from the Issuer and issued to the Issuer call options with respect to the Class A Common Stock and Class B Common Stock of the Issuer (the "Call Options"), each of which options expired on October 31, 2020. On October 16, 2020 the Issuer and the Funds entered into an Amendment to the Option Agreement (the "Amendment") that extended the expiration date of both the Put Options and the Call Options to December 31, 2020. The Amendment is reported in this Form 4 as (i) a cancellation of the original Put Options and Call Options and (ii) an issuance of replacement Put Options by the Issuer to the Funds and replacement Call Options by the Funds to the Issuer.

F3 · derivative.exercise_date: In a Form 4 filed on May 27, 2020, the Funds reported that they entered into Put/Call Option and Consent Agreement (the "Option Agreement") dated as of May 25, 2020 with the Issuer pursuant to which the Funds acquired the Put Options from the Issuer and issued to the Issuer call options with respect to the Class A Common Stock and Class B Common Stock of the Issuer (the "Call Options"), each of which options expired on October 31, 2020. On October 16, 2020 the Issuer and the Funds entered into an Amendment to the Option Agreement (the "Amendment") that extended the expiration date of both the Put Options and the Call Options to December 31, 2020. The Amendment is reported in this Form 4 as (i) a cancellation of the original Put Options and Call Options and (ii) an issuance of replacement Put Options by the Issuer to the Funds and replacement Call Options by the Funds to the Issuer.

F5 · derivative.exercise_date: Pursuant to the Option Agreement, both of the Put Options and the Call Options will become exercisable upon the closing date of a merger involving the Issuer, certain subsidiaries thereof, Solara Holdings, LLC and certain entities related thereto.

F6 · derivative.underlying: Pursuant to the Option Agreement, the Put Options and Call Options each relate to the shares of Class A Common Stock and Class B Common Stock held by the Funds, without distinguishing between such shares.

F1 · ownership.nature: The filing of this Form 4 shall not be construed as an admission that Assured Investment Management LLC (f/k/a BlueMountain Capital Management, LLC) ("AssuredIM") is or was for the purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise the beneficial owner of any put options ("Put Options") relating to shares of Class A Common Stock, par value $0.0001 per share "Class A Common Stock") and Class B Common Stock, par value $0.0001 per share ("Class B Common Stock"), of AdaptHealth Corp. (the "Issuer"). Pursuant to Rule 16a-1(a)(4) of the Exchange Act, AssuredIM disclaims such beneficial ownership, except to the extent of its pecuniary interest.

F2 · ownership.nature: AssuredIM is the investment manager of each of: (i) BMSB L.P. ("BMSB"); (ii) BlueMountain Fursan Fund L.P. ("FRSN"); (iii) BlueMountain Foinaven Master Fund L.P. ("BMFV"); and (iv) BlueMountain Summit Opportunities Fund II (US) L.P. (together with BMSB, FRSN and BMFV, the "Funds"), which collectively are the direct beneficial owners of 1,898,967 Put Options. AssuredIM, although it directs the exercise of the Put Options held by the Funds, only receives an asset-based fee relating to the Put Options held by the Funds.

SEC source: 0000899243-20-028730 · doc4.xml · derivative · entry 3

Assured Investment Management LLC · CIK 0001427430 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Footnotes

Disclosed balance after: 1,898,967

Underlying: Class A and B Common Stock · 1,898,967 shares

Expires 2020-10-31

F1 · security: The filing of this Form 4 shall not be construed as an admission that Assured Investment Management LLC (f/k/a BlueMountain Capital Management, LLC) ("AssuredIM") is or was for the purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise the beneficial owner of any put options ("Put Options") relating to shares of Class A Common Stock, par value $0.0001 per share "Class A Common Stock") and Class B Common Stock, par value $0.0001 per share ("Class B Common Stock"), of AdaptHealth Corp. (the "Issuer"). Pursuant to Rule 16a-1(a)(4) of the Exchange Act, AssuredIM disclaims such beneficial ownership, except to the extent of its pecuniary interest.

F2 · security: AssuredIM is the investment manager of each of: (i) BMSB L.P. ("BMSB"); (ii) BlueMountain Fursan Fund L.P. ("FRSN"); (iii) BlueMountain Foinaven Master Fund L.P. ("BMFV"); and (iv) BlueMountain Summit Opportunities Fund II (US) L.P. (together with BMSB, FRSN and BMFV, the "Funds"), which collectively are the direct beneficial owners of 1,898,967 Put Options. AssuredIM, although it directs the exercise of the Put Options held by the Funds, only receives an asset-based fee relating to the Put Options held by the Funds.

F3 · security: In a Form 4 filed on May 27, 2020, the Funds reported that they entered into Put/Call Option and Consent Agreement (the "Option Agreement") dated as of May 25, 2020 with the Issuer pursuant to which the Funds acquired the Put Options from the Issuer and issued to the Issuer call options with respect to the Class A Common Stock and Class B Common Stock of the Issuer (the "Call Options"), each of which options expired on October 31, 2020. On October 16, 2020 the Issuer and the Funds entered into an Amendment to the Option Agreement (the "Amendment") that extended the expiration date of both the Put Options and the Call Options to December 31, 2020. The Amendment is reported in this Form 4 as (i) a cancellation of the original Put Options and Call Options and (ii) an issuance of replacement Put Options by the Issuer to the Funds and replacement Call Options by the Funds to the Issuer.

F4 · security: Pursuant to the Option Agreement, the Put Options may be exercised by the Funds at a per option price equal to the greater of (x) $14.50 and (y) 85% of the current market value of a share of Class A Common Stock on the date the Put Options are exercised, as determined in accordance with the terms of the Option Agreement.

F5 · security: Pursuant to the Option Agreement, both of the Put Options and the Call Options will become exercisable upon the closing date of a merger involving the Issuer, certain subsidiaries thereof, Solara Holdings, LLC and certain entities related thereto.

F6 · security: Pursuant to the Option Agreement, the Put Options and Call Options each relate to the shares of Class A Common Stock and Class B Common Stock held by the Funds, without distinguishing between such shares.

F4 · derivative.exercise_price: Pursuant to the Option Agreement, the Put Options may be exercised by the Funds at a per option price equal to the greater of (x) $14.50 and (y) 85% of the current market value of a share of Class A Common Stock on the date the Put Options are exercised, as determined in accordance with the terms of the Option Agreement.

F3 · kind: In a Form 4 filed on May 27, 2020, the Funds reported that they entered into Put/Call Option and Consent Agreement (the "Option Agreement") dated as of May 25, 2020 with the Issuer pursuant to which the Funds acquired the Put Options from the Issuer and issued to the Issuer call options with respect to the Class A Common Stock and Class B Common Stock of the Issuer (the "Call Options"), each of which options expired on October 31, 2020. On October 16, 2020 the Issuer and the Funds entered into an Amendment to the Option Agreement (the "Amendment") that extended the expiration date of both the Put Options and the Call Options to December 31, 2020. The Amendment is reported in this Form 4 as (i) a cancellation of the original Put Options and Call Options and (ii) an issuance of replacement Put Options by the Issuer to the Funds and replacement Call Options by the Funds to the Issuer.

F3 · derivative.exercise_date: In a Form 4 filed on May 27, 2020, the Funds reported that they entered into Put/Call Option and Consent Agreement (the "Option Agreement") dated as of May 25, 2020 with the Issuer pursuant to which the Funds acquired the Put Options from the Issuer and issued to the Issuer call options with respect to the Class A Common Stock and Class B Common Stock of the Issuer (the "Call Options"), each of which options expired on October 31, 2020. On October 16, 2020 the Issuer and the Funds entered into an Amendment to the Option Agreement (the "Amendment") that extended the expiration date of both the Put Options and the Call Options to December 31, 2020. The Amendment is reported in this Form 4 as (i) a cancellation of the original Put Options and Call Options and (ii) an issuance of replacement Put Options by the Issuer to the Funds and replacement Call Options by the Funds to the Issuer.

F5 · derivative.exercise_date: Pursuant to the Option Agreement, both of the Put Options and the Call Options will become exercisable upon the closing date of a merger involving the Issuer, certain subsidiaries thereof, Solara Holdings, LLC and certain entities related thereto.

F6 · derivative.underlying: Pursuant to the Option Agreement, the Put Options and Call Options each relate to the shares of Class A Common Stock and Class B Common Stock held by the Funds, without distinguishing between such shares.

F1 · ownership.nature: The filing of this Form 4 shall not be construed as an admission that Assured Investment Management LLC (f/k/a BlueMountain Capital Management, LLC) ("AssuredIM") is or was for the purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise the beneficial owner of any put options ("Put Options") relating to shares of Class A Common Stock, par value $0.0001 per share "Class A Common Stock") and Class B Common Stock, par value $0.0001 per share ("Class B Common Stock"), of AdaptHealth Corp. (the "Issuer"). Pursuant to Rule 16a-1(a)(4) of the Exchange Act, AssuredIM disclaims such beneficial ownership, except to the extent of its pecuniary interest.

F2 · ownership.nature: AssuredIM is the investment manager of each of: (i) BMSB L.P. ("BMSB"); (ii) BlueMountain Fursan Fund L.P. ("FRSN"); (iii) BlueMountain Foinaven Master Fund L.P. ("BMFV"); and (iv) BlueMountain Summit Opportunities Fund II (US) L.P. (together with BMSB, FRSN and BMFV, the "Funds"), which collectively are the direct beneficial owners of 1,898,967 Put Options. AssuredIM, although it directs the exercise of the Put Options held by the Funds, only receives an asset-based fee relating to the Put Options held by the Funds.

SEC source: 0000899243-20-028730 · doc4.xml · derivative · entry 2

Assured Investment Management LLC · CIK 0001427430 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Footnotes

Disclosed balance after: 0

Underlying: Class A and B Common Stock · 1,898,967 shares

Expires 2020-10-31

F1 · security: The filing of this Form 4 shall not be construed as an admission that Assured Investment Management LLC (f/k/a BlueMountain Capital Management, LLC) ("AssuredIM") is or was for the purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise the beneficial owner of any put options ("Put Options") relating to shares of Class A Common Stock, par value $0.0001 per share "Class A Common Stock") and Class B Common Stock, par value $0.0001 per share ("Class B Common Stock"), of AdaptHealth Corp. (the "Issuer"). Pursuant to Rule 16a-1(a)(4) of the Exchange Act, AssuredIM disclaims such beneficial ownership, except to the extent of its pecuniary interest.

F2 · security: AssuredIM is the investment manager of each of: (i) BMSB L.P. ("BMSB"); (ii) BlueMountain Fursan Fund L.P. ("FRSN"); (iii) BlueMountain Foinaven Master Fund L.P. ("BMFV"); and (iv) BlueMountain Summit Opportunities Fund II (US) L.P. (together with BMSB, FRSN and BMFV, the "Funds"), which collectively are the direct beneficial owners of 1,898,967 Put Options. AssuredIM, although it directs the exercise of the Put Options held by the Funds, only receives an asset-based fee relating to the Put Options held by the Funds.

F3 · security: In a Form 4 filed on May 27, 2020, the Funds reported that they entered into Put/Call Option and Consent Agreement (the "Option Agreement") dated as of May 25, 2020 with the Issuer pursuant to which the Funds acquired the Put Options from the Issuer and issued to the Issuer call options with respect to the Class A Common Stock and Class B Common Stock of the Issuer (the "Call Options"), each of which options expired on October 31, 2020. On October 16, 2020 the Issuer and the Funds entered into an Amendment to the Option Agreement (the "Amendment") that extended the expiration date of both the Put Options and the Call Options to December 31, 2020. The Amendment is reported in this Form 4 as (i) a cancellation of the original Put Options and Call Options and (ii) an issuance of replacement Put Options by the Issuer to the Funds and replacement Call Options by the Funds to the Issuer.

F4 · security: Pursuant to the Option Agreement, the Put Options may be exercised by the Funds at a per option price equal to the greater of (x) $14.50 and (y) 85% of the current market value of a share of Class A Common Stock on the date the Put Options are exercised, as determined in accordance with the terms of the Option Agreement.

F5 · security: Pursuant to the Option Agreement, both of the Put Options and the Call Options will become exercisable upon the closing date of a merger involving the Issuer, certain subsidiaries thereof, Solara Holdings, LLC and certain entities related thereto.

F6 · security: Pursuant to the Option Agreement, the Put Options and Call Options each relate to the shares of Class A Common Stock and Class B Common Stock held by the Funds, without distinguishing between such shares.

F3 · kind: In a Form 4 filed on May 27, 2020, the Funds reported that they entered into Put/Call Option and Consent Agreement (the "Option Agreement") dated as of May 25, 2020 with the Issuer pursuant to which the Funds acquired the Put Options from the Issuer and issued to the Issuer call options with respect to the Class A Common Stock and Class B Common Stock of the Issuer (the "Call Options"), each of which options expired on October 31, 2020. On October 16, 2020 the Issuer and the Funds entered into an Amendment to the Option Agreement (the "Amendment") that extended the expiration date of both the Put Options and the Call Options to December 31, 2020. The Amendment is reported in this Form 4 as (i) a cancellation of the original Put Options and Call Options and (ii) an issuance of replacement Put Options by the Issuer to the Funds and replacement Call Options by the Funds to the Issuer.

F3 · derivative.exercise_date: In a Form 4 filed on May 27, 2020, the Funds reported that they entered into Put/Call Option and Consent Agreement (the "Option Agreement") dated as of May 25, 2020 with the Issuer pursuant to which the Funds acquired the Put Options from the Issuer and issued to the Issuer call options with respect to the Class A Common Stock and Class B Common Stock of the Issuer (the "Call Options"), each of which options expired on October 31, 2020. On October 16, 2020 the Issuer and the Funds entered into an Amendment to the Option Agreement (the "Amendment") that extended the expiration date of both the Put Options and the Call Options to December 31, 2020. The Amendment is reported in this Form 4 as (i) a cancellation of the original Put Options and Call Options and (ii) an issuance of replacement Put Options by the Issuer to the Funds and replacement Call Options by the Funds to the Issuer.

F5 · derivative.exercise_date: Pursuant to the Option Agreement, both of the Put Options and the Call Options will become exercisable upon the closing date of a merger involving the Issuer, certain subsidiaries thereof, Solara Holdings, LLC and certain entities related thereto.

F6 · derivative.underlying: Pursuant to the Option Agreement, the Put Options and Call Options each relate to the shares of Class A Common Stock and Class B Common Stock held by the Funds, without distinguishing between such shares.

F1 · ownership.nature: The filing of this Form 4 shall not be construed as an admission that Assured Investment Management LLC (f/k/a BlueMountain Capital Management, LLC) ("AssuredIM") is or was for the purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise the beneficial owner of any put options ("Put Options") relating to shares of Class A Common Stock, par value $0.0001 per share "Class A Common Stock") and Class B Common Stock, par value $0.0001 per share ("Class B Common Stock"), of AdaptHealth Corp. (the "Issuer"). Pursuant to Rule 16a-1(a)(4) of the Exchange Act, AssuredIM disclaims such beneficial ownership, except to the extent of its pecuniary interest.

F2 · ownership.nature: AssuredIM is the investment manager of each of: (i) BMSB L.P. ("BMSB"); (ii) BlueMountain Fursan Fund L.P. ("FRSN"); (iii) BlueMountain Foinaven Master Fund L.P. ("BMFV"); and (iv) BlueMountain Summit Opportunities Fund II (US) L.P. (together with BMSB, FRSN and BMFV, the "Funds"), which collectively are the direct beneficial owners of 1,898,967 Put Options. AssuredIM, although it directs the exercise of the Put Options held by the Funds, only receives an asset-based fee relating to the Put Options held by the Funds.

SEC source: 0000899243-20-028730 · doc4.xml · derivative · entry 1

Assured Investment Management LLC · CIK 0001427430 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Footnotes

Disclosed balance after: 0

Underlying: Class A and B Common Stock · 1,898,967 shares

Expires 2020-10-31

F1 · security: The filing of this Form 4 shall not be construed as an admission that Assured Investment Management LLC (f/k/a BlueMountain Capital Management, LLC) ("AssuredIM") is or was for the purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise the beneficial owner of any put options ("Put Options") relating to shares of Class A Common Stock, par value $0.0001 per share "Class A Common Stock") and Class B Common Stock, par value $0.0001 per share ("Class B Common Stock"), of AdaptHealth Corp. (the "Issuer"). Pursuant to Rule 16a-1(a)(4) of the Exchange Act, AssuredIM disclaims such beneficial ownership, except to the extent of its pecuniary interest.

F2 · security: AssuredIM is the investment manager of each of: (i) BMSB L.P. ("BMSB"); (ii) BlueMountain Fursan Fund L.P. ("FRSN"); (iii) BlueMountain Foinaven Master Fund L.P. ("BMFV"); and (iv) BlueMountain Summit Opportunities Fund II (US) L.P. (together with BMSB, FRSN and BMFV, the "Funds"), which collectively are the direct beneficial owners of 1,898,967 Put Options. AssuredIM, although it directs the exercise of the Put Options held by the Funds, only receives an asset-based fee relating to the Put Options held by the Funds.

F3 · security: In a Form 4 filed on May 27, 2020, the Funds reported that they entered into Put/Call Option and Consent Agreement (the "Option Agreement") dated as of May 25, 2020 with the Issuer pursuant to which the Funds acquired the Put Options from the Issuer and issued to the Issuer call options with respect to the Class A Common Stock and Class B Common Stock of the Issuer (the "Call Options"), each of which options expired on October 31, 2020. On October 16, 2020 the Issuer and the Funds entered into an Amendment to the Option Agreement (the "Amendment") that extended the expiration date of both the Put Options and the Call Options to December 31, 2020. The Amendment is reported in this Form 4 as (i) a cancellation of the original Put Options and Call Options and (ii) an issuance of replacement Put Options by the Issuer to the Funds and replacement Call Options by the Funds to the Issuer.

F4 · security: Pursuant to the Option Agreement, the Put Options may be exercised by the Funds at a per option price equal to the greater of (x) $14.50 and (y) 85% of the current market value of a share of Class A Common Stock on the date the Put Options are exercised, as determined in accordance with the terms of the Option Agreement.

F5 · security: Pursuant to the Option Agreement, both of the Put Options and the Call Options will become exercisable upon the closing date of a merger involving the Issuer, certain subsidiaries thereof, Solara Holdings, LLC and certain entities related thereto.

F6 · security: Pursuant to the Option Agreement, the Put Options and Call Options each relate to the shares of Class A Common Stock and Class B Common Stock held by the Funds, without distinguishing between such shares.

F4 · derivative.exercise_price: Pursuant to the Option Agreement, the Put Options may be exercised by the Funds at a per option price equal to the greater of (x) $14.50 and (y) 85% of the current market value of a share of Class A Common Stock on the date the Put Options are exercised, as determined in accordance with the terms of the Option Agreement.

F3 · kind: In a Form 4 filed on May 27, 2020, the Funds reported that they entered into Put/Call Option and Consent Agreement (the "Option Agreement") dated as of May 25, 2020 with the Issuer pursuant to which the Funds acquired the Put Options from the Issuer and issued to the Issuer call options with respect to the Class A Common Stock and Class B Common Stock of the Issuer (the "Call Options"), each of which options expired on October 31, 2020. On October 16, 2020 the Issuer and the Funds entered into an Amendment to the Option Agreement (the "Amendment") that extended the expiration date of both the Put Options and the Call Options to December 31, 2020. The Amendment is reported in this Form 4 as (i) a cancellation of the original Put Options and Call Options and (ii) an issuance of replacement Put Options by the Issuer to the Funds and replacement Call Options by the Funds to the Issuer.

F3 · derivative.exercise_date: In a Form 4 filed on May 27, 2020, the Funds reported that they entered into Put/Call Option and Consent Agreement (the "Option Agreement") dated as of May 25, 2020 with the Issuer pursuant to which the Funds acquired the Put Options from the Issuer and issued to the Issuer call options with respect to the Class A Common Stock and Class B Common Stock of the Issuer (the "Call Options"), each of which options expired on October 31, 2020. On October 16, 2020 the Issuer and the Funds entered into an Amendment to the Option Agreement (the "Amendment") that extended the expiration date of both the Put Options and the Call Options to December 31, 2020. The Amendment is reported in this Form 4 as (i) a cancellation of the original Put Options and Call Options and (ii) an issuance of replacement Put Options by the Issuer to the Funds and replacement Call Options by the Funds to the Issuer.

F5 · derivative.exercise_date: Pursuant to the Option Agreement, both of the Put Options and the Call Options will become exercisable upon the closing date of a merger involving the Issuer, certain subsidiaries thereof, Solara Holdings, LLC and certain entities related thereto.

F6 · derivative.underlying: Pursuant to the Option Agreement, the Put Options and Call Options each relate to the shares of Class A Common Stock and Class B Common Stock held by the Funds, without distinguishing between such shares.

F1 · ownership.nature: The filing of this Form 4 shall not be construed as an admission that Assured Investment Management LLC (f/k/a BlueMountain Capital Management, LLC) ("AssuredIM") is or was for the purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise the beneficial owner of any put options ("Put Options") relating to shares of Class A Common Stock, par value $0.0001 per share "Class A Common Stock") and Class B Common Stock, par value $0.0001 per share ("Class B Common Stock"), of AdaptHealth Corp. (the "Issuer"). Pursuant to Rule 16a-1(a)(4) of the Exchange Act, AssuredIM disclaims such beneficial ownership, except to the extent of its pecuniary interest.

F2 · ownership.nature: AssuredIM is the investment manager of each of: (i) BMSB L.P. ("BMSB"); (ii) BlueMountain Fursan Fund L.P. ("FRSN"); (iii) BlueMountain Foinaven Master Fund L.P. ("BMFV"); and (iv) BlueMountain Summit Opportunities Fund II (US) L.P. (together with BMSB, FRSN and BMFV, the "Funds"), which collectively are the direct beneficial owners of 1,898,967 Put Options. AssuredIM, although it directs the exercise of the Put Options held by the Funds, only receives an asset-based fee relating to the Put Options held by the Funds.

SEC source: 0000899243-20-024933 · doc4.xml · derivative · entry 2

OEP VII GP, L.L.C. · CIK 0001817118 · 10% owner

OEP AHCO Investment Holdings, LLC · CIK 0001817112 · 10% owner

ONE EQUITY PARTNERS VII, L.P. · CIK 0001733523 · 10% owner

ONE EQUITY PARTNERS VII-A, L.P. · CIK 0001733525 · 10% owner

ONE EQUITY PARTNERS VII-B, L.P. · CIK 0001733528 · 10% owner

OEP VII Project A Co-Investment Partners, L.P. · CIK 0001817120 · 10% owner

OEP VII PROJECT A-I CO-INVESTMENT PARTNERS, L.P. · CIK 0001821208 · 10% owner

OEP VII General Partner, L.P. · CIK 0001817115 · 10% owner

CASHIN RICHARD M JR · CIK 0001172898 · 10% owner

Han David · CIK 0001817107 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 0

Underlying: Class A Common Stock · 2,887,709 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: The number of shares of Class A Common Stock of AdaptHealth Corp., a Delaware corporation (the "Issuer"), having par value of $0.0001 per share (the "Class A Common Stock"), deliverable upon conversion of each share of Series A Convertible Preferred Stock, par value $0.0001 per share (the "Series A Preferred Stock"), is equal to 72.727273 shares, subject to customary anti-dilution and other adjustments. The terms of the Series A Preferred Stock generally restrict the conversion of such shares until the shares of Class A Common Stock issuable upon conversion thereof has been approved by stockholders of the Issuer in accordance with Nasdaq Listing Rules. Such stockholder approval was obtained on August 27, 2020. The Series A Preferred Stock has no expiration date.

F3 · kind: The Reporting Persons are filing this Form 4 to report the conversion by the Issuer (as defined below) of 39,706 shares of Series A Preferred Stock (as defined below), resulting in the acquisition by the Reporting Persons of 2,887,709 shares of Class A Common Stock (as defined below).

F3 · price: The Reporting Persons are filing this Form 4 to report the conversion by the Issuer (as defined below) of 39,706 shares of Series A Preferred Stock (as defined below), resulting in the acquisition by the Reporting Persons of 2,887,709 shares of Class A Common Stock (as defined below).

F4 · price: The number of shares of Class A Common Stock of AdaptHealth Corp., a Delaware corporation (the "Issuer"), having par value of $0.0001 per share (the "Class A Common Stock"), deliverable upon conversion of each share of Series A Convertible Preferred Stock, par value $0.0001 per share (the "Series A Preferred Stock"), is equal to 72.727273 shares, subject to customary anti-dilution and other adjustments. The terms of the Series A Preferred Stock generally restrict the conversion of such shares until the shares of Class A Common Stock issuable upon conversion thereof has been approved by stockholders of the Issuer in accordance with Nasdaq Listing Rules. Such stockholder approval was obtained on August 27, 2020. The Series A Preferred Stock has no expiration date.

F4 · derivative.exercise_date: The number of shares of Class A Common Stock of AdaptHealth Corp., a Delaware corporation (the "Issuer"), having par value of $0.0001 per share (the "Class A Common Stock"), deliverable upon conversion of each share of Series A Convertible Preferred Stock, par value $0.0001 per share (the "Series A Preferred Stock"), is equal to 72.727273 shares, subject to customary anti-dilution and other adjustments. The terms of the Series A Preferred Stock generally restrict the conversion of such shares until the shares of Class A Common Stock issuable upon conversion thereof has been approved by stockholders of the Issuer in accordance with Nasdaq Listing Rules. Such stockholder approval was obtained on August 27, 2020. The Series A Preferred Stock has no expiration date.

F4 · derivative.expiration_date: The number of shares of Class A Common Stock of AdaptHealth Corp., a Delaware corporation (the "Issuer"), having par value of $0.0001 per share (the "Class A Common Stock"), deliverable upon conversion of each share of Series A Convertible Preferred Stock, par value $0.0001 per share (the "Series A Preferred Stock"), is equal to 72.727273 shares, subject to customary anti-dilution and other adjustments. The terms of the Series A Preferred Stock generally restrict the conversion of such shares until the shares of Class A Common Stock issuable upon conversion thereof has been approved by stockholders of the Issuer in accordance with Nasdaq Listing Rules. Such stockholder approval was obtained on August 27, 2020. The Series A Preferred Stock has no expiration date.

F3 · derivative.underlying_shares: The Reporting Persons are filing this Form 4 to report the conversion by the Issuer (as defined below) of 39,706 shares of Series A Preferred Stock (as defined below), resulting in the acquisition by the Reporting Persons of 2,887,709 shares of Class A Common Stock (as defined below).

F4 · derivative.underlying_shares: The number of shares of Class A Common Stock of AdaptHealth Corp., a Delaware corporation (the "Issuer"), having par value of $0.0001 per share (the "Class A Common Stock"), deliverable upon conversion of each share of Series A Convertible Preferred Stock, par value $0.0001 per share (the "Series A Preferred Stock"), is equal to 72.727273 shares, subject to customary anti-dilution and other adjustments. The terms of the Series A Preferred Stock generally restrict the conversion of such shares until the shares of Class A Common Stock issuable upon conversion thereof has been approved by stockholders of the Issuer in accordance with Nasdaq Listing Rules. Such stockholder approval was obtained on August 27, 2020. The Series A Preferred Stock has no expiration date.

F3 · balance_after: The Reporting Persons are filing this Form 4 to report the conversion by the Issuer (as defined below) of 39,706 shares of Series A Preferred Stock (as defined below), resulting in the acquisition by the Reporting Persons of 2,887,709 shares of Class A Common Stock (as defined below).

F4 · balance_after: The number of shares of Class A Common Stock of AdaptHealth Corp., a Delaware corporation (the "Issuer"), having par value of $0.0001 per share (the "Class A Common Stock"), deliverable upon conversion of each share of Series A Convertible Preferred Stock, par value $0.0001 per share (the "Series A Preferred Stock"), is equal to 72.727273 shares, subject to customary anti-dilution and other adjustments. The terms of the Series A Preferred Stock generally restrict the conversion of such shares until the shares of Class A Common Stock issuable upon conversion thereof has been approved by stockholders of the Issuer in accordance with Nasdaq Listing Rules. Such stockholder approval was obtained on August 27, 2020. The Series A Preferred Stock has no expiration date.

F1 · ownership.nature: These securities are held directly by OEP AHCO Investment Holdings, LLC ("Investor"). Investor is owned by One Equity Partners VII, L.P., a Cayman Islands exempted limited partnership ("OEP VII LP"), One Equity Partners VII-A, L.P., a Cayman Islands exempted limited partnership ("OEP VII-A LP"), One Equity Partners VII-B, L.P., a Delaware limited partnership ("OEP VII-B LP"), OEP VII Project A Co-Investment Partners, L.P., a Delaware limited partnership ("OEP VII Project A LP") and OEP VII Project A-I Co-Investment Partners, L.P., a Delaware limited partnership ("OEP VII Project A-I LP" and, together with OEP VII LP, OEP VII-A LP, OEP VII-B LP and OEP VII Project A LP, the "Parallel Funds"). The general partner of each of the Parallel Funds is OEP VII General Partner, L.P., a Cayman Islands exempted limited partnership ("OEP VII GP"), and the general partner of OEP VIIGP is OEP VII GP, L.L.C., a Cayman Islands limited liability company ("OEP VII GP LLC").

F2 · ownership.nature: (Continued from Footnote 1) OEP VII GP LLC is member-managed by Messrs. Richard Cashin and David Han. By virtue of the relationships described above, each of the Parallel Funds, OEP VII GP, OEP VII GP LLC and Messrs. Richard Cashin and David Han may be deemed to beneficially own, and share voting and dispositive power with respect to, the securities held directly by Investor. Each of the reporting persons disclaims beneficial ownership of the securities except to the extent of its or his pecuniary interest therein.

SEC source: 0000899243-20-024933 · doc4.xml · nonDerivative · entry 1

OEP VII GP, L.L.C. · CIK 0001817118 · 10% owner

OEP AHCO Investment Holdings, LLC · CIK 0001817112 · 10% owner

ONE EQUITY PARTNERS VII, L.P. · CIK 0001733523 · 10% owner

ONE EQUITY PARTNERS VII-A, L.P. · CIK 0001733525 · 10% owner

ONE EQUITY PARTNERS VII-B, L.P. · CIK 0001733528 · 10% owner

OEP VII Project A Co-Investment Partners, L.P. · CIK 0001817120 · 10% owner

OEP VII PROJECT A-I CO-INVESTMENT PARTNERS, L.P. · CIK 0001821208 · 10% owner

OEP VII General Partner, L.P. · CIK 0001817115 · 10% owner

CASHIN RICHARD M JR · CIK 0001172898 · 10% owner

Han David · CIK 0001817107 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 13,818,180

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · kind: The Reporting Persons are filing this Form 4 to report the conversion by the Issuer (as defined below) of 39,706 shares of Series A Preferred Stock (as defined below), resulting in the acquisition by the Reporting Persons of 2,887,709 shares of Class A Common Stock (as defined below).

F3 · shares: The Reporting Persons are filing this Form 4 to report the conversion by the Issuer (as defined below) of 39,706 shares of Series A Preferred Stock (as defined below), resulting in the acquisition by the Reporting Persons of 2,887,709 shares of Class A Common Stock (as defined below).

F3 · price: The Reporting Persons are filing this Form 4 to report the conversion by the Issuer (as defined below) of 39,706 shares of Series A Preferred Stock (as defined below), resulting in the acquisition by the Reporting Persons of 2,887,709 shares of Class A Common Stock (as defined below).

F3 · acquired: The Reporting Persons are filing this Form 4 to report the conversion by the Issuer (as defined below) of 39,706 shares of Series A Preferred Stock (as defined below), resulting in the acquisition by the Reporting Persons of 2,887,709 shares of Class A Common Stock (as defined below).

F1 · balance_after: These securities are held directly by OEP AHCO Investment Holdings, LLC ("Investor"). Investor is owned by One Equity Partners VII, L.P., a Cayman Islands exempted limited partnership ("OEP VII LP"), One Equity Partners VII-A, L.P., a Cayman Islands exempted limited partnership ("OEP VII-A LP"), One Equity Partners VII-B, L.P., a Delaware limited partnership ("OEP VII-B LP"), OEP VII Project A Co-Investment Partners, L.P., a Delaware limited partnership ("OEP VII Project A LP") and OEP VII Project A-I Co-Investment Partners, L.P., a Delaware limited partnership ("OEP VII Project A-I LP" and, together with OEP VII LP, OEP VII-A LP, OEP VII-B LP and OEP VII Project A LP, the "Parallel Funds"). The general partner of each of the Parallel Funds is OEP VII General Partner, L.P., a Cayman Islands exempted limited partnership ("OEP VII GP"), and the general partner of OEP VIIGP is OEP VII GP, L.L.C., a Cayman Islands limited liability company ("OEP VII GP LLC").

F2 · balance_after: (Continued from Footnote 1) OEP VII GP LLC is member-managed by Messrs. Richard Cashin and David Han. By virtue of the relationships described above, each of the Parallel Funds, OEP VII GP, OEP VII GP LLC and Messrs. Richard Cashin and David Han may be deemed to beneficially own, and share voting and dispositive power with respect to, the securities held directly by Investor. Each of the reporting persons disclaims beneficial ownership of the securities except to the extent of its or his pecuniary interest therein.

F3 · balance_after: The Reporting Persons are filing this Form 4 to report the conversion by the Issuer (as defined below) of 39,706 shares of Series A Preferred Stock (as defined below), resulting in the acquisition by the Reporting Persons of 2,887,709 shares of Class A Common Stock (as defined below).

F1 · ownership.nature: These securities are held directly by OEP AHCO Investment Holdings, LLC ("Investor"). Investor is owned by One Equity Partners VII, L.P., a Cayman Islands exempted limited partnership ("OEP VII LP"), One Equity Partners VII-A, L.P., a Cayman Islands exempted limited partnership ("OEP VII-A LP"), One Equity Partners VII-B, L.P., a Delaware limited partnership ("OEP VII-B LP"), OEP VII Project A Co-Investment Partners, L.P., a Delaware limited partnership ("OEP VII Project A LP") and OEP VII Project A-I Co-Investment Partners, L.P., a Delaware limited partnership ("OEP VII Project A-I LP" and, together with OEP VII LP, OEP VII-A LP, OEP VII-B LP and OEP VII Project A LP, the "Parallel Funds"). The general partner of each of the Parallel Funds is OEP VII General Partner, L.P., a Cayman Islands exempted limited partnership ("OEP VII GP"), and the general partner of OEP VIIGP is OEP VII GP, L.L.C., a Cayman Islands limited liability company ("OEP VII GP LLC").

F2 · ownership.nature: (Continued from Footnote 1) OEP VII GP LLC is member-managed by Messrs. Richard Cashin and David Han. By virtue of the relationships described above, each of the Parallel Funds, OEP VII GP, OEP VII GP LLC and Messrs. Richard Cashin and David Han may be deemed to beneficially own, and share voting and dispositive power with respect to, the securities held directly by Investor. Each of the reporting persons disclaims beneficial ownership of the securities except to the extent of its or his pecuniary interest therein.

SEC source: 0001104659-20-104533 · a4.xml · nonDerivative · entry 1

QUASHA ALAN G · CIK 0000921100 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,886

SEC source: 0001104659-20-104528 · a4.xml · nonDerivative · entry 1

BARASCH RICHARD A · CIK 0001076341 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 344,920

F1 · balance_after: Includes 5,000 shares previously granted to the reporting person that were inadvertently omitted from the reporting person's Form 4 filed on December 18, 2019.

SEC source: 0001104659-20-104530 · a4.xml · nonDerivative · entry 1

Williams David Solomon III · CIK 0001820444 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,509

SEC source: 0001104659-20-104534 · a4.xml · nonDerivative · entry 1

Connors Terence J · CIK 0001689279 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,509

SEC source: 0001104659-20-104532 · a4.xml · nonDerivative · entry 1

Weaver Susan T · CIK 0001687804 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,509

SEC source: 0001104659-20-104531 · a4.xml · nonDerivative · entry 1

Coppens Bradley J · CIK 0001487729 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,509

SEC source: 0001104659-20-104529 · a4.xml · nonDerivative · entry 1

WOLF DALE B · CIK 0001228861 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,009

SEC source: 0000899243-20-023282 · doc4.xml · derivative · entry 4

OEP VII GP, L.L.C. · CIK 0001817118 · 10% owner

OEP AHCO Investment Holdings, LLC · CIK 0001817112 · 10% owner

ONE EQUITY PARTNERS VII, L.P. · CIK 0001733523 · 10% owner

ONE EQUITY PARTNERS VII-A, L.P. · CIK 0001733525 · 10% owner

ONE EQUITY PARTNERS VII-B, L.P. · CIK 0001733528 · 10% owner

OEP VII Project A Co-Investment Partners, L.P. · CIK 0001817120 · 10% owner

OEP VII PROJECT A-I CO-INVESTMENT PARTNERS, L.P. · CIK 0001821208 · 10% owner

OEP VII General Partner, L.P. · CIK 0001817115 · 10% owner

CASHIN RICHARD M JR · CIK 0001172898 · 10% owner

Han David · CIK 0001817107 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 39,706

Underlying: Class A Common Stock · 396,650 shares

Expires not disclosed

F4 · derivative.exercise_price: The number of shares of Class A Common Stock of AdaptHealth Corp., a Delaware corporation (the "Issuer"), having par value of $0.0001 per share (the "Class A Common Stock"), deliverable upon conversion of each share of Series A Convertible Preferred Stock, par value $0.0001 per share (the "Series A Preferred Stock"), is equal to 72.727273 shares, subject to customary anti-dilution and other adjustments. The terms of the Series A Preferred Stock generally restrict the conversion of such shares until the shares of Class A Common Stock issuable upon conversion thereof has been approved by stockholders of the Issuer in accordance with Nasdaq Listing Rules. Thereafter, the holder or the Issuer may convert the Series A Preferred Stock. The Series A Preferred Stock has no expiration date.

F3 · kind: In connection with a re-allocation of ownership interests in Investor, the reporting persons are filing this Form 4 to report the acquisition by each of OEP VII Project A LP and OEP Project A-I LP of membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisitions. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transactions.

F3 · shares: In connection with a re-allocation of ownership interests in Investor, the reporting persons are filing this Form 4 to report the acquisition by each of OEP VII Project A LP and OEP Project A-I LP of membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisitions. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transactions.

F3 · price: In connection with a re-allocation of ownership interests in Investor, the reporting persons are filing this Form 4 to report the acquisition by each of OEP VII Project A LP and OEP Project A-I LP of membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisitions. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transactions.

F4 · price: The number of shares of Class A Common Stock of AdaptHealth Corp., a Delaware corporation (the "Issuer"), having par value of $0.0001 per share (the "Class A Common Stock"), deliverable upon conversion of each share of Series A Convertible Preferred Stock, par value $0.0001 per share (the "Series A Preferred Stock"), is equal to 72.727273 shares, subject to customary anti-dilution and other adjustments. The terms of the Series A Preferred Stock generally restrict the conversion of such shares until the shares of Class A Common Stock issuable upon conversion thereof has been approved by stockholders of the Issuer in accordance with Nasdaq Listing Rules. Thereafter, the holder or the Issuer may convert the Series A Preferred Stock. The Series A Preferred Stock has no expiration date.

F4 · derivative.exercise_date: The number of shares of Class A Common Stock of AdaptHealth Corp., a Delaware corporation (the "Issuer"), having par value of $0.0001 per share (the "Class A Common Stock"), deliverable upon conversion of each share of Series A Convertible Preferred Stock, par value $0.0001 per share (the "Series A Preferred Stock"), is equal to 72.727273 shares, subject to customary anti-dilution and other adjustments. The terms of the Series A Preferred Stock generally restrict the conversion of such shares until the shares of Class A Common Stock issuable upon conversion thereof has been approved by stockholders of the Issuer in accordance with Nasdaq Listing Rules. Thereafter, the holder or the Issuer may convert the Series A Preferred Stock. The Series A Preferred Stock has no expiration date.

F4 · derivative.expiration_date: The number of shares of Class A Common Stock of AdaptHealth Corp., a Delaware corporation (the "Issuer"), having par value of $0.0001 per share (the "Class A Common Stock"), deliverable upon conversion of each share of Series A Convertible Preferred Stock, par value $0.0001 per share (the "Series A Preferred Stock"), is equal to 72.727273 shares, subject to customary anti-dilution and other adjustments. The terms of the Series A Preferred Stock generally restrict the conversion of such shares until the shares of Class A Common Stock issuable upon conversion thereof has been approved by stockholders of the Issuer in accordance with Nasdaq Listing Rules. Thereafter, the holder or the Issuer may convert the Series A Preferred Stock. The Series A Preferred Stock has no expiration date.

F3 · derivative.underlying_shares: In connection with a re-allocation of ownership interests in Investor, the reporting persons are filing this Form 4 to report the acquisition by each of OEP VII Project A LP and OEP Project A-I LP of membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisitions. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transactions.

F4 · derivative.underlying_shares: The number of shares of Class A Common Stock of AdaptHealth Corp., a Delaware corporation (the "Issuer"), having par value of $0.0001 per share (the "Class A Common Stock"), deliverable upon conversion of each share of Series A Convertible Preferred Stock, par value $0.0001 per share (the "Series A Preferred Stock"), is equal to 72.727273 shares, subject to customary anti-dilution and other adjustments. The terms of the Series A Preferred Stock generally restrict the conversion of such shares until the shares of Class A Common Stock issuable upon conversion thereof has been approved by stockholders of the Issuer in accordance with Nasdaq Listing Rules. Thereafter, the holder or the Issuer may convert the Series A Preferred Stock. The Series A Preferred Stock has no expiration date.

F3 · balance_after: In connection with a re-allocation of ownership interests in Investor, the reporting persons are filing this Form 4 to report the acquisition by each of OEP VII Project A LP and OEP Project A-I LP of membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisitions. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transactions.

F4 · balance_after: The number of shares of Class A Common Stock of AdaptHealth Corp., a Delaware corporation (the "Issuer"), having par value of $0.0001 per share (the "Class A Common Stock"), deliverable upon conversion of each share of Series A Convertible Preferred Stock, par value $0.0001 per share (the "Series A Preferred Stock"), is equal to 72.727273 shares, subject to customary anti-dilution and other adjustments. The terms of the Series A Preferred Stock generally restrict the conversion of such shares until the shares of Class A Common Stock issuable upon conversion thereof has been approved by stockholders of the Issuer in accordance with Nasdaq Listing Rules. Thereafter, the holder or the Issuer may convert the Series A Preferred Stock. The Series A Preferred Stock has no expiration date.

F1 · ownership.nature: These securities are held directly by OEP AHCO Investment Holdings, LLC ("Investor"). Investor is owned by One Equity Partners VII, L.P., a Cayman Islands exempted limited partnership ("OEP VII LP"), One Equity Partners VII-A, L.P., a Cayman Islands exempted limited partnership ("OEP VII-A LP"), One Equity Partners VII-B, L.P., a Delaware limited partnership ("OEP VII-B LP"), OEP VII Project A Co-Investment Partners, L.P., a Delaware limited partnership ("OEP VII Project A LP") and OEP VII Project A-I Co-Investment Partners, L.P., a Delaware limited partnership ("OEP VII Project A-I LP" and, together with OEP VII LP, OEP VII-A LP, OEP VII-B LP and OEP VII Project A LP, the "Parallel Funds"). The general partner of each of the Parallel Funds is OEP VII General Partner, L.P., a Cayman Islands exempted limited partnership ("OEP VII GP"), and the general partner of OEP VIIGP is OEP VII GP, L.L.C., a Cayman Islands limited liability company ("OEP VII GP LLC").

F2 · ownership.nature: (Continued from Footnote 1) OEP VII GP LLC is member-managed by Messrs. Richard Cashin and David Han. By virtue of the relationships described above, each of the Parallel Funds, OEP VII GP, OEP VII GP LLC and Messrs. Richard Cashin and David Han may be deemed to beneficially own, and share voting and dispositive power with respect to, the securities held directly by Investor. Each of the reporting persons disclaims beneficial ownership of the securities except to the extent of its or his pecuniary interest therein.

SEC source: 0000899243-20-023282 · doc4.xml · derivative · entry 3

OEP VII GP, L.L.C. · CIK 0001817118 · 10% owner

OEP AHCO Investment Holdings, LLC · CIK 0001817112 · 10% owner

ONE EQUITY PARTNERS VII, L.P. · CIK 0001733523 · 10% owner

ONE EQUITY PARTNERS VII-A, L.P. · CIK 0001733525 · 10% owner

ONE EQUITY PARTNERS VII-B, L.P. · CIK 0001733528 · 10% owner

OEP VII Project A Co-Investment Partners, L.P. · CIK 0001817120 · 10% owner

OEP VII PROJECT A-I CO-INVESTMENT PARTNERS, L.P. · CIK 0001821208 · 10% owner

OEP VII General Partner, L.P. · CIK 0001817115 · 10% owner

CASHIN RICHARD M JR · CIK 0001172898 · 10% owner

Han David · CIK 0001817107 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 39,706

Underlying: Class A Common Stock · 396,650 shares

Expires not disclosed

F4 · derivative.exercise_price: The number of shares of Class A Common Stock of AdaptHealth Corp., a Delaware corporation (the "Issuer"), having par value of $0.0001 per share (the "Class A Common Stock"), deliverable upon conversion of each share of Series A Convertible Preferred Stock, par value $0.0001 per share (the "Series A Preferred Stock"), is equal to 72.727273 shares, subject to customary anti-dilution and other adjustments. The terms of the Series A Preferred Stock generally restrict the conversion of such shares until the shares of Class A Common Stock issuable upon conversion thereof has been approved by stockholders of the Issuer in accordance with Nasdaq Listing Rules. Thereafter, the holder or the Issuer may convert the Series A Preferred Stock. The Series A Preferred Stock has no expiration date.

F3 · kind: In connection with a re-allocation of ownership interests in Investor, the reporting persons are filing this Form 4 to report the acquisition by each of OEP VII Project A LP and OEP Project A-I LP of membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisitions. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transactions.

F3 · shares: In connection with a re-allocation of ownership interests in Investor, the reporting persons are filing this Form 4 to report the acquisition by each of OEP VII Project A LP and OEP Project A-I LP of membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisitions. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transactions.

F3 · price: In connection with a re-allocation of ownership interests in Investor, the reporting persons are filing this Form 4 to report the acquisition by each of OEP VII Project A LP and OEP Project A-I LP of membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisitions. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transactions.

F4 · price: The number of shares of Class A Common Stock of AdaptHealth Corp., a Delaware corporation (the "Issuer"), having par value of $0.0001 per share (the "Class A Common Stock"), deliverable upon conversion of each share of Series A Convertible Preferred Stock, par value $0.0001 per share (the "Series A Preferred Stock"), is equal to 72.727273 shares, subject to customary anti-dilution and other adjustments. The terms of the Series A Preferred Stock generally restrict the conversion of such shares until the shares of Class A Common Stock issuable upon conversion thereof has been approved by stockholders of the Issuer in accordance with Nasdaq Listing Rules. Thereafter, the holder or the Issuer may convert the Series A Preferred Stock. The Series A Preferred Stock has no expiration date.

F4 · derivative.exercise_date: The number of shares of Class A Common Stock of AdaptHealth Corp., a Delaware corporation (the "Issuer"), having par value of $0.0001 per share (the "Class A Common Stock"), deliverable upon conversion of each share of Series A Convertible Preferred Stock, par value $0.0001 per share (the "Series A Preferred Stock"), is equal to 72.727273 shares, subject to customary anti-dilution and other adjustments. The terms of the Series A Preferred Stock generally restrict the conversion of such shares until the shares of Class A Common Stock issuable upon conversion thereof has been approved by stockholders of the Issuer in accordance with Nasdaq Listing Rules. Thereafter, the holder or the Issuer may convert the Series A Preferred Stock. The Series A Preferred Stock has no expiration date.

F4 · derivative.expiration_date: The number of shares of Class A Common Stock of AdaptHealth Corp., a Delaware corporation (the "Issuer"), having par value of $0.0001 per share (the "Class A Common Stock"), deliverable upon conversion of each share of Series A Convertible Preferred Stock, par value $0.0001 per share (the "Series A Preferred Stock"), is equal to 72.727273 shares, subject to customary anti-dilution and other adjustments. The terms of the Series A Preferred Stock generally restrict the conversion of such shares until the shares of Class A Common Stock issuable upon conversion thereof has been approved by stockholders of the Issuer in accordance with Nasdaq Listing Rules. Thereafter, the holder or the Issuer may convert the Series A Preferred Stock. The Series A Preferred Stock has no expiration date.

F3 · derivative.underlying_shares: In connection with a re-allocation of ownership interests in Investor, the reporting persons are filing this Form 4 to report the acquisition by each of OEP VII Project A LP and OEP Project A-I LP of membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisitions. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transactions.

F4 · derivative.underlying_shares: The number of shares of Class A Common Stock of AdaptHealth Corp., a Delaware corporation (the "Issuer"), having par value of $0.0001 per share (the "Class A Common Stock"), deliverable upon conversion of each share of Series A Convertible Preferred Stock, par value $0.0001 per share (the "Series A Preferred Stock"), is equal to 72.727273 shares, subject to customary anti-dilution and other adjustments. The terms of the Series A Preferred Stock generally restrict the conversion of such shares until the shares of Class A Common Stock issuable upon conversion thereof has been approved by stockholders of the Issuer in accordance with Nasdaq Listing Rules. Thereafter, the holder or the Issuer may convert the Series A Preferred Stock. The Series A Preferred Stock has no expiration date.

F3 · balance_after: In connection with a re-allocation of ownership interests in Investor, the reporting persons are filing this Form 4 to report the acquisition by each of OEP VII Project A LP and OEP Project A-I LP of membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisitions. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transactions.

F4 · balance_after: The number of shares of Class A Common Stock of AdaptHealth Corp., a Delaware corporation (the "Issuer"), having par value of $0.0001 per share (the "Class A Common Stock"), deliverable upon conversion of each share of Series A Convertible Preferred Stock, par value $0.0001 per share (the "Series A Preferred Stock"), is equal to 72.727273 shares, subject to customary anti-dilution and other adjustments. The terms of the Series A Preferred Stock generally restrict the conversion of such shares until the shares of Class A Common Stock issuable upon conversion thereof has been approved by stockholders of the Issuer in accordance with Nasdaq Listing Rules. Thereafter, the holder or the Issuer may convert the Series A Preferred Stock. The Series A Preferred Stock has no expiration date.

F1 · ownership.nature: These securities are held directly by OEP AHCO Investment Holdings, LLC ("Investor"). Investor is owned by One Equity Partners VII, L.P., a Cayman Islands exempted limited partnership ("OEP VII LP"), One Equity Partners VII-A, L.P., a Cayman Islands exempted limited partnership ("OEP VII-A LP"), One Equity Partners VII-B, L.P., a Delaware limited partnership ("OEP VII-B LP"), OEP VII Project A Co-Investment Partners, L.P., a Delaware limited partnership ("OEP VII Project A LP") and OEP VII Project A-I Co-Investment Partners, L.P., a Delaware limited partnership ("OEP VII Project A-I LP" and, together with OEP VII LP, OEP VII-A LP, OEP VII-B LP and OEP VII Project A LP, the "Parallel Funds"). The general partner of each of the Parallel Funds is OEP VII General Partner, L.P., a Cayman Islands exempted limited partnership ("OEP VII GP"), and the general partner of OEP VIIGP is OEP VII GP, L.L.C., a Cayman Islands limited liability company ("OEP VII GP LLC").

F2 · ownership.nature: (Continued from Footnote 1) OEP VII GP LLC is member-managed by Messrs. Richard Cashin and David Han. By virtue of the relationships described above, each of the Parallel Funds, OEP VII GP, OEP VII GP LLC and Messrs. Richard Cashin and David Han may be deemed to beneficially own, and share voting and dispositive power with respect to, the securities held directly by Investor. Each of the reporting persons disclaims beneficial ownership of the securities except to the extent of its or his pecuniary interest therein.

SEC source: 0000899243-20-023282 · doc4.xml · nonDerivative · entry 2

OEP VII GP, L.L.C. · CIK 0001817118 · 10% owner

OEP AHCO Investment Holdings, LLC · CIK 0001817112 · 10% owner

ONE EQUITY PARTNERS VII, L.P. · CIK 0001733523 · 10% owner

ONE EQUITY PARTNERS VII-A, L.P. · CIK 0001733525 · 10% owner

ONE EQUITY PARTNERS VII-B, L.P. · CIK 0001733528 · 10% owner

OEP VII Project A Co-Investment Partners, L.P. · CIK 0001817120 · 10% owner

OEP VII PROJECT A-I CO-INVESTMENT PARTNERS, L.P. · CIK 0001821208 · 10% owner

OEP VII General Partner, L.P. · CIK 0001817115 · 10% owner

CASHIN RICHARD M JR · CIK 0001172898 · 10% owner

Han David · CIK 0001817107 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 10,930,471

F3 · kind: In connection with a re-allocation of ownership interests in Investor, the reporting persons are filing this Form 4 to report the acquisition by each of OEP VII Project A LP and OEP Project A-I LP of membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisitions. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transactions.

F3 · shares: In connection with a re-allocation of ownership interests in Investor, the reporting persons are filing this Form 4 to report the acquisition by each of OEP VII Project A LP and OEP Project A-I LP of membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisitions. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transactions.

F3 · price: In connection with a re-allocation of ownership interests in Investor, the reporting persons are filing this Form 4 to report the acquisition by each of OEP VII Project A LP and OEP Project A-I LP of membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisitions. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transactions.

F3 · acquired: In connection with a re-allocation of ownership interests in Investor, the reporting persons are filing this Form 4 to report the acquisition by each of OEP VII Project A LP and OEP Project A-I LP of membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisitions. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transactions.

F1 · balance_after: These securities are held directly by OEP AHCO Investment Holdings, LLC ("Investor"). Investor is owned by One Equity Partners VII, L.P., a Cayman Islands exempted limited partnership ("OEP VII LP"), One Equity Partners VII-A, L.P., a Cayman Islands exempted limited partnership ("OEP VII-A LP"), One Equity Partners VII-B, L.P., a Delaware limited partnership ("OEP VII-B LP"), OEP VII Project A Co-Investment Partners, L.P., a Delaware limited partnership ("OEP VII Project A LP") and OEP VII Project A-I Co-Investment Partners, L.P., a Delaware limited partnership ("OEP VII Project A-I LP" and, together with OEP VII LP, OEP VII-A LP, OEP VII-B LP and OEP VII Project A LP, the "Parallel Funds"). The general partner of each of the Parallel Funds is OEP VII General Partner, L.P., a Cayman Islands exempted limited partnership ("OEP VII GP"), and the general partner of OEP VIIGP is OEP VII GP, L.L.C., a Cayman Islands limited liability company ("OEP VII GP LLC").

F2 · balance_after: (Continued from Footnote 1) OEP VII GP LLC is member-managed by Messrs. Richard Cashin and David Han. By virtue of the relationships described above, each of the Parallel Funds, OEP VII GP, OEP VII GP LLC and Messrs. Richard Cashin and David Han may be deemed to beneficially own, and share voting and dispositive power with respect to, the securities held directly by Investor. Each of the reporting persons disclaims beneficial ownership of the securities except to the extent of its or his pecuniary interest therein.

F3 · balance_after: In connection with a re-allocation of ownership interests in Investor, the reporting persons are filing this Form 4 to report the acquisition by each of OEP VII Project A LP and OEP Project A-I LP of membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisitions. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transactions.

F1 · ownership.nature: These securities are held directly by OEP AHCO Investment Holdings, LLC ("Investor"). Investor is owned by One Equity Partners VII, L.P., a Cayman Islands exempted limited partnership ("OEP VII LP"), One Equity Partners VII-A, L.P., a Cayman Islands exempted limited partnership ("OEP VII-A LP"), One Equity Partners VII-B, L.P., a Delaware limited partnership ("OEP VII-B LP"), OEP VII Project A Co-Investment Partners, L.P., a Delaware limited partnership ("OEP VII Project A LP") and OEP VII Project A-I Co-Investment Partners, L.P., a Delaware limited partnership ("OEP VII Project A-I LP" and, together with OEP VII LP, OEP VII-A LP, OEP VII-B LP and OEP VII Project A LP, the "Parallel Funds"). The general partner of each of the Parallel Funds is OEP VII General Partner, L.P., a Cayman Islands exempted limited partnership ("OEP VII GP"), and the general partner of OEP VIIGP is OEP VII GP, L.L.C., a Cayman Islands limited liability company ("OEP VII GP LLC").

F2 · ownership.nature: (Continued from Footnote 1) OEP VII GP LLC is member-managed by Messrs. Richard Cashin and David Han. By virtue of the relationships described above, each of the Parallel Funds, OEP VII GP, OEP VII GP LLC and Messrs. Richard Cashin and David Han may be deemed to beneficially own, and share voting and dispositive power with respect to, the securities held directly by Investor. Each of the reporting persons disclaims beneficial ownership of the securities except to the extent of its or his pecuniary interest therein.

SEC source: 0000899243-20-023282 · doc4.xml · nonDerivative · entry 1

OEP VII GP, L.L.C. · CIK 0001817118 · 10% owner

OEP AHCO Investment Holdings, LLC · CIK 0001817112 · 10% owner

ONE EQUITY PARTNERS VII, L.P. · CIK 0001733523 · 10% owner

ONE EQUITY PARTNERS VII-A, L.P. · CIK 0001733525 · 10% owner

ONE EQUITY PARTNERS VII-B, L.P. · CIK 0001733528 · 10% owner

OEP VII Project A Co-Investment Partners, L.P. · CIK 0001817120 · 10% owner

OEP VII PROJECT A-I CO-INVESTMENT PARTNERS, L.P. · CIK 0001821208 · 10% owner

OEP VII General Partner, L.P. · CIK 0001817115 · 10% owner

CASHIN RICHARD M JR · CIK 0001172898 · 10% owner

Han David · CIK 0001817107 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 10,930,471

F3 · kind: In connection with a re-allocation of ownership interests in Investor, the reporting persons are filing this Form 4 to report the acquisition by each of OEP VII Project A LP and OEP Project A-I LP of membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisitions. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transactions.

F3 · shares: In connection with a re-allocation of ownership interests in Investor, the reporting persons are filing this Form 4 to report the acquisition by each of OEP VII Project A LP and OEP Project A-I LP of membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisitions. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transactions.

F3 · price: In connection with a re-allocation of ownership interests in Investor, the reporting persons are filing this Form 4 to report the acquisition by each of OEP VII Project A LP and OEP Project A-I LP of membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisitions. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transactions.

F3 · acquired: In connection with a re-allocation of ownership interests in Investor, the reporting persons are filing this Form 4 to report the acquisition by each of OEP VII Project A LP and OEP Project A-I LP of membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisitions. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transactions.

F1 · balance_after: These securities are held directly by OEP AHCO Investment Holdings, LLC ("Investor"). Investor is owned by One Equity Partners VII, L.P., a Cayman Islands exempted limited partnership ("OEP VII LP"), One Equity Partners VII-A, L.P., a Cayman Islands exempted limited partnership ("OEP VII-A LP"), One Equity Partners VII-B, L.P., a Delaware limited partnership ("OEP VII-B LP"), OEP VII Project A Co-Investment Partners, L.P., a Delaware limited partnership ("OEP VII Project A LP") and OEP VII Project A-I Co-Investment Partners, L.P., a Delaware limited partnership ("OEP VII Project A-I LP" and, together with OEP VII LP, OEP VII-A LP, OEP VII-B LP and OEP VII Project A LP, the "Parallel Funds"). The general partner of each of the Parallel Funds is OEP VII General Partner, L.P., a Cayman Islands exempted limited partnership ("OEP VII GP"), and the general partner of OEP VIIGP is OEP VII GP, L.L.C., a Cayman Islands limited liability company ("OEP VII GP LLC").

F2 · balance_after: (Continued from Footnote 1) OEP VII GP LLC is member-managed by Messrs. Richard Cashin and David Han. By virtue of the relationships described above, each of the Parallel Funds, OEP VII GP, OEP VII GP LLC and Messrs. Richard Cashin and David Han may be deemed to beneficially own, and share voting and dispositive power with respect to, the securities held directly by Investor. Each of the reporting persons disclaims beneficial ownership of the securities except to the extent of its or his pecuniary interest therein.

F3 · balance_after: In connection with a re-allocation of ownership interests in Investor, the reporting persons are filing this Form 4 to report the acquisition by each of OEP VII Project A LP and OEP Project A-I LP of membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisitions. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transactions.

F1 · ownership.nature: These securities are held directly by OEP AHCO Investment Holdings, LLC ("Investor"). Investor is owned by One Equity Partners VII, L.P., a Cayman Islands exempted limited partnership ("OEP VII LP"), One Equity Partners VII-A, L.P., a Cayman Islands exempted limited partnership ("OEP VII-A LP"), One Equity Partners VII-B, L.P., a Delaware limited partnership ("OEP VII-B LP"), OEP VII Project A Co-Investment Partners, L.P., a Delaware limited partnership ("OEP VII Project A LP") and OEP VII Project A-I Co-Investment Partners, L.P., a Delaware limited partnership ("OEP VII Project A-I LP" and, together with OEP VII LP, OEP VII-A LP, OEP VII-B LP and OEP VII Project A LP, the "Parallel Funds"). The general partner of each of the Parallel Funds is OEP VII General Partner, L.P., a Cayman Islands exempted limited partnership ("OEP VII GP"), and the general partner of OEP VIIGP is OEP VII GP, L.L.C., a Cayman Islands limited liability company ("OEP VII GP LLC").

F2 · ownership.nature: (Continued from Footnote 1) OEP VII GP LLC is member-managed by Messrs. Richard Cashin and David Han. By virtue of the relationships described above, each of the Parallel Funds, OEP VII GP, OEP VII GP LLC and Messrs. Richard Cashin and David Han may be deemed to beneficially own, and share voting and dispositive power with respect to, the securities held directly by Investor. Each of the reporting persons disclaims beneficial ownership of the securities except to the extent of its or his pecuniary interest therein.

SEC source: 0001104659-20-094178 · a4.xml · nonDerivative · entry 1

Clemens Jason A · CIK 0001820867 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 59,418

SEC source: 0000899243-20-021871 · doc4.xml · derivative · entry 4

OEP VII GP, L.L.C. · CIK 0001817118 · 10% owner

OEP AHCO Investment Holdings, LLC · CIK 0001817112 · 10% owner

ONE EQUITY PARTNERS VII, L.P. · CIK 0001733523 · 10% owner

ONE EQUITY PARTNERS VII-A, L.P. · CIK 0001733525 · 10% owner

ONE EQUITY PARTNERS VII-B, L.P. · CIK 0001733528 · 10% owner

OEP VII Project A Co-Investment Partners, L.P. · CIK 0001817120 · 10% owner

OEP VII General Partner, L.P. · CIK 0001817115 · 10% owner

CASHIN RICHARD M JR · CIK 0001172898 · 10% owner

Han David · CIK 0001817107 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 39,706

Underlying: Class A Common Stock · 227,927 shares

Expires not disclosed

F4 · derivative.exercise_price: The number of shares of Class A Common Stock of AdaptHealth Corp., a Delaware corporation (the "Issuer"), having par value of $0.0001 per share (the "Class A Common Stock"), deliverable upon conversion of each share of Series A Convertible Preferred Stock, par value $0.0001 per share (the "Series A Preferred Stock"), is equal to 72.727273 shares, subject to customary anti-dilution and other adjustments. The terms of the Series A Preferred Stock generally restrict the conversion of such shares until the shares of Class A Common Stock issuable upon conversion thereof has been approved by stockholders of the Issuer in accordance with Nasdaq Listing Rules. Thereafter, the holder or the Issuer may convert the Series A Preferred Stock. The Series A Preferred Stock has no expiration date.

F3 · kind: In connection with a re-allocation of ownership interests in Investor, the Reporting Persons are filing this Form 4 to report the acquisition by OEP VII Project A LP of additional membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisition. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transaction.

F3 · shares: In connection with a re-allocation of ownership interests in Investor, the Reporting Persons are filing this Form 4 to report the acquisition by OEP VII Project A LP of additional membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisition. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transaction.

F3 · price: In connection with a re-allocation of ownership interests in Investor, the Reporting Persons are filing this Form 4 to report the acquisition by OEP VII Project A LP of additional membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisition. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transaction.

F4 · price: The number of shares of Class A Common Stock of AdaptHealth Corp., a Delaware corporation (the "Issuer"), having par value of $0.0001 per share (the "Class A Common Stock"), deliverable upon conversion of each share of Series A Convertible Preferred Stock, par value $0.0001 per share (the "Series A Preferred Stock"), is equal to 72.727273 shares, subject to customary anti-dilution and other adjustments. The terms of the Series A Preferred Stock generally restrict the conversion of such shares until the shares of Class A Common Stock issuable upon conversion thereof has been approved by stockholders of the Issuer in accordance with Nasdaq Listing Rules. Thereafter, the holder or the Issuer may convert the Series A Preferred Stock. The Series A Preferred Stock has no expiration date.

F4 · derivative.exercise_date: The number of shares of Class A Common Stock of AdaptHealth Corp., a Delaware corporation (the "Issuer"), having par value of $0.0001 per share (the "Class A Common Stock"), deliverable upon conversion of each share of Series A Convertible Preferred Stock, par value $0.0001 per share (the "Series A Preferred Stock"), is equal to 72.727273 shares, subject to customary anti-dilution and other adjustments. The terms of the Series A Preferred Stock generally restrict the conversion of such shares until the shares of Class A Common Stock issuable upon conversion thereof has been approved by stockholders of the Issuer in accordance with Nasdaq Listing Rules. Thereafter, the holder or the Issuer may convert the Series A Preferred Stock. The Series A Preferred Stock has no expiration date.

F4 · derivative.expiration_date: The number of shares of Class A Common Stock of AdaptHealth Corp., a Delaware corporation (the "Issuer"), having par value of $0.0001 per share (the "Class A Common Stock"), deliverable upon conversion of each share of Series A Convertible Preferred Stock, par value $0.0001 per share (the "Series A Preferred Stock"), is equal to 72.727273 shares, subject to customary anti-dilution and other adjustments. The terms of the Series A Preferred Stock generally restrict the conversion of such shares until the shares of Class A Common Stock issuable upon conversion thereof has been approved by stockholders of the Issuer in accordance with Nasdaq Listing Rules. Thereafter, the holder or the Issuer may convert the Series A Preferred Stock. The Series A Preferred Stock has no expiration date.

F3 · derivative.underlying_shares: In connection with a re-allocation of ownership interests in Investor, the Reporting Persons are filing this Form 4 to report the acquisition by OEP VII Project A LP of additional membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisition. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transaction.

F4 · derivative.underlying_shares: The number of shares of Class A Common Stock of AdaptHealth Corp., a Delaware corporation (the "Issuer"), having par value of $0.0001 per share (the "Class A Common Stock"), deliverable upon conversion of each share of Series A Convertible Preferred Stock, par value $0.0001 per share (the "Series A Preferred Stock"), is equal to 72.727273 shares, subject to customary anti-dilution and other adjustments. The terms of the Series A Preferred Stock generally restrict the conversion of such shares until the shares of Class A Common Stock issuable upon conversion thereof has been approved by stockholders of the Issuer in accordance with Nasdaq Listing Rules. Thereafter, the holder or the Issuer may convert the Series A Preferred Stock. The Series A Preferred Stock has no expiration date.

F3 · balance_after: In connection with a re-allocation of ownership interests in Investor, the Reporting Persons are filing this Form 4 to report the acquisition by OEP VII Project A LP of additional membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisition. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transaction.

F4 · balance_after: The number of shares of Class A Common Stock of AdaptHealth Corp., a Delaware corporation (the "Issuer"), having par value of $0.0001 per share (the "Class A Common Stock"), deliverable upon conversion of each share of Series A Convertible Preferred Stock, par value $0.0001 per share (the "Series A Preferred Stock"), is equal to 72.727273 shares, subject to customary anti-dilution and other adjustments. The terms of the Series A Preferred Stock generally restrict the conversion of such shares until the shares of Class A Common Stock issuable upon conversion thereof has been approved by stockholders of the Issuer in accordance with Nasdaq Listing Rules. Thereafter, the holder or the Issuer may convert the Series A Preferred Stock. The Series A Preferred Stock has no expiration date.

F1 · ownership.nature: These securities are held directly by OEP AHCO Investment Holdings, LLC ("Investor"). Investor is owned by One Equity Partners VII, L.P., a Cayman Islands exempted limited partnership ("OEP VII LP"), One Equity Partners VII-A, L.P., a Cayman Islands exempted limited partnership ("OEP VII-A LP"), One Equity Partners VII-B, L.P., a Delaware limited partnership ("OEP VII-B LP"), and OEP VII Project A Co-Investment Partners, L.P., a Delaware limited partnership ("OEP VII Project A LP" and, together with OEP VII LP, OEP VII-A LP and OEP VII-B LP, the "Parallel Funds"). The general partner of each of the Parallel Funds is OEP VII General Partner, L.P., a Cayman Islands exempted limited partnership ("OEP VII GP"), and the general partner of OEP VII GP is OEP VII GP, L.L.C., a Cayman Islands limited liability company ("OEP VII GP LLC"). OEP VII GP LLC is member-managed by Messrs. Richard Cashin and David Han.

F2 · ownership.nature: (Continued from Footnote 1) By virtue of the relationships described above, each of the Parallel Funds, OEP VII GP, OEP VII GP LLC and Messrs. Richard Cashin and David Han may be deemed to beneficially own, and share voting and dispositive power with respect to, the securities held directly by Investor. Each of the reporting persons disclaims beneficial ownership of the securities except to the extent of its or his pecuniary interest therein.

SEC source: 0000899243-20-021871 · doc4.xml · derivative · entry 3

OEP VII GP, L.L.C. · CIK 0001817118 · 10% owner

OEP AHCO Investment Holdings, LLC · CIK 0001817112 · 10% owner

ONE EQUITY PARTNERS VII, L.P. · CIK 0001733523 · 10% owner

ONE EQUITY PARTNERS VII-A, L.P. · CIK 0001733525 · 10% owner

ONE EQUITY PARTNERS VII-B, L.P. · CIK 0001733528 · 10% owner

OEP VII Project A Co-Investment Partners, L.P. · CIK 0001817120 · 10% owner

OEP VII General Partner, L.P. · CIK 0001817115 · 10% owner

CASHIN RICHARD M JR · CIK 0001172898 · 10% owner

Han David · CIK 0001817107 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 39,706

Underlying: Class A Common Stock · 227,927 shares

Expires not disclosed

F4 · derivative.exercise_price: The number of shares of Class A Common Stock of AdaptHealth Corp., a Delaware corporation (the "Issuer"), having par value of $0.0001 per share (the "Class A Common Stock"), deliverable upon conversion of each share of Series A Convertible Preferred Stock, par value $0.0001 per share (the "Series A Preferred Stock"), is equal to 72.727273 shares, subject to customary anti-dilution and other adjustments. The terms of the Series A Preferred Stock generally restrict the conversion of such shares until the shares of Class A Common Stock issuable upon conversion thereof has been approved by stockholders of the Issuer in accordance with Nasdaq Listing Rules. Thereafter, the holder or the Issuer may convert the Series A Preferred Stock. The Series A Preferred Stock has no expiration date.

F3 · kind: In connection with a re-allocation of ownership interests in Investor, the Reporting Persons are filing this Form 4 to report the acquisition by OEP VII Project A LP of additional membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisition. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transaction.

F3 · shares: In connection with a re-allocation of ownership interests in Investor, the Reporting Persons are filing this Form 4 to report the acquisition by OEP VII Project A LP of additional membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisition. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transaction.

F3 · price: In connection with a re-allocation of ownership interests in Investor, the Reporting Persons are filing this Form 4 to report the acquisition by OEP VII Project A LP of additional membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisition. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transaction.

F4 · price: The number of shares of Class A Common Stock of AdaptHealth Corp., a Delaware corporation (the "Issuer"), having par value of $0.0001 per share (the "Class A Common Stock"), deliverable upon conversion of each share of Series A Convertible Preferred Stock, par value $0.0001 per share (the "Series A Preferred Stock"), is equal to 72.727273 shares, subject to customary anti-dilution and other adjustments. The terms of the Series A Preferred Stock generally restrict the conversion of such shares until the shares of Class A Common Stock issuable upon conversion thereof has been approved by stockholders of the Issuer in accordance with Nasdaq Listing Rules. Thereafter, the holder or the Issuer may convert the Series A Preferred Stock. The Series A Preferred Stock has no expiration date.

F4 · derivative.exercise_date: The number of shares of Class A Common Stock of AdaptHealth Corp., a Delaware corporation (the "Issuer"), having par value of $0.0001 per share (the "Class A Common Stock"), deliverable upon conversion of each share of Series A Convertible Preferred Stock, par value $0.0001 per share (the "Series A Preferred Stock"), is equal to 72.727273 shares, subject to customary anti-dilution and other adjustments. The terms of the Series A Preferred Stock generally restrict the conversion of such shares until the shares of Class A Common Stock issuable upon conversion thereof has been approved by stockholders of the Issuer in accordance with Nasdaq Listing Rules. Thereafter, the holder or the Issuer may convert the Series A Preferred Stock. The Series A Preferred Stock has no expiration date.

F4 · derivative.expiration_date: The number of shares of Class A Common Stock of AdaptHealth Corp., a Delaware corporation (the "Issuer"), having par value of $0.0001 per share (the "Class A Common Stock"), deliverable upon conversion of each share of Series A Convertible Preferred Stock, par value $0.0001 per share (the "Series A Preferred Stock"), is equal to 72.727273 shares, subject to customary anti-dilution and other adjustments. The terms of the Series A Preferred Stock generally restrict the conversion of such shares until the shares of Class A Common Stock issuable upon conversion thereof has been approved by stockholders of the Issuer in accordance with Nasdaq Listing Rules. Thereafter, the holder or the Issuer may convert the Series A Preferred Stock. The Series A Preferred Stock has no expiration date.

F3 · derivative.underlying_shares: In connection with a re-allocation of ownership interests in Investor, the Reporting Persons are filing this Form 4 to report the acquisition by OEP VII Project A LP of additional membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisition. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transaction.

F4 · derivative.underlying_shares: The number of shares of Class A Common Stock of AdaptHealth Corp., a Delaware corporation (the "Issuer"), having par value of $0.0001 per share (the "Class A Common Stock"), deliverable upon conversion of each share of Series A Convertible Preferred Stock, par value $0.0001 per share (the "Series A Preferred Stock"), is equal to 72.727273 shares, subject to customary anti-dilution and other adjustments. The terms of the Series A Preferred Stock generally restrict the conversion of such shares until the shares of Class A Common Stock issuable upon conversion thereof has been approved by stockholders of the Issuer in accordance with Nasdaq Listing Rules. Thereafter, the holder or the Issuer may convert the Series A Preferred Stock. The Series A Preferred Stock has no expiration date.

F3 · balance_after: In connection with a re-allocation of ownership interests in Investor, the Reporting Persons are filing this Form 4 to report the acquisition by OEP VII Project A LP of additional membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisition. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transaction.

F4 · balance_after: The number of shares of Class A Common Stock of AdaptHealth Corp., a Delaware corporation (the "Issuer"), having par value of $0.0001 per share (the "Class A Common Stock"), deliverable upon conversion of each share of Series A Convertible Preferred Stock, par value $0.0001 per share (the "Series A Preferred Stock"), is equal to 72.727273 shares, subject to customary anti-dilution and other adjustments. The terms of the Series A Preferred Stock generally restrict the conversion of such shares until the shares of Class A Common Stock issuable upon conversion thereof has been approved by stockholders of the Issuer in accordance with Nasdaq Listing Rules. Thereafter, the holder or the Issuer may convert the Series A Preferred Stock. The Series A Preferred Stock has no expiration date.

F1 · ownership.nature: These securities are held directly by OEP AHCO Investment Holdings, LLC ("Investor"). Investor is owned by One Equity Partners VII, L.P., a Cayman Islands exempted limited partnership ("OEP VII LP"), One Equity Partners VII-A, L.P., a Cayman Islands exempted limited partnership ("OEP VII-A LP"), One Equity Partners VII-B, L.P., a Delaware limited partnership ("OEP VII-B LP"), and OEP VII Project A Co-Investment Partners, L.P., a Delaware limited partnership ("OEP VII Project A LP" and, together with OEP VII LP, OEP VII-A LP and OEP VII-B LP, the "Parallel Funds"). The general partner of each of the Parallel Funds is OEP VII General Partner, L.P., a Cayman Islands exempted limited partnership ("OEP VII GP"), and the general partner of OEP VII GP is OEP VII GP, L.L.C., a Cayman Islands limited liability company ("OEP VII GP LLC"). OEP VII GP LLC is member-managed by Messrs. Richard Cashin and David Han.

F2 · ownership.nature: (Continued from Footnote 1) By virtue of the relationships described above, each of the Parallel Funds, OEP VII GP, OEP VII GP LLC and Messrs. Richard Cashin and David Han may be deemed to beneficially own, and share voting and dispositive power with respect to, the securities held directly by Investor. Each of the reporting persons disclaims beneficial ownership of the securities except to the extent of its or his pecuniary interest therein.

SEC source: 0000899243-20-021871 · doc4.xml · nonDerivative · entry 2

OEP VII GP, L.L.C. · CIK 0001817118 · 10% owner

OEP AHCO Investment Holdings, LLC · CIK 0001817112 · 10% owner

ONE EQUITY PARTNERS VII, L.P. · CIK 0001733523 · 10% owner

ONE EQUITY PARTNERS VII-A, L.P. · CIK 0001733525 · 10% owner

ONE EQUITY PARTNERS VII-B, L.P. · CIK 0001733528 · 10% owner

OEP VII Project A Co-Investment Partners, L.P. · CIK 0001817120 · 10% owner

OEP VII General Partner, L.P. · CIK 0001817115 · 10% owner

CASHIN RICHARD M JR · CIK 0001172898 · 10% owner

Han David · CIK 0001817107 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 10,930,471

F3 · kind: In connection with a re-allocation of ownership interests in Investor, the Reporting Persons are filing this Form 4 to report the acquisition by OEP VII Project A LP of additional membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisition. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transaction.

F3 · shares: In connection with a re-allocation of ownership interests in Investor, the Reporting Persons are filing this Form 4 to report the acquisition by OEP VII Project A LP of additional membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisition. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transaction.

F3 · price: In connection with a re-allocation of ownership interests in Investor, the Reporting Persons are filing this Form 4 to report the acquisition by OEP VII Project A LP of additional membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisition. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transaction.

F3 · acquired: In connection with a re-allocation of ownership interests in Investor, the Reporting Persons are filing this Form 4 to report the acquisition by OEP VII Project A LP of additional membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisition. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transaction.

F1 · balance_after: These securities are held directly by OEP AHCO Investment Holdings, LLC ("Investor"). Investor is owned by One Equity Partners VII, L.P., a Cayman Islands exempted limited partnership ("OEP VII LP"), One Equity Partners VII-A, L.P., a Cayman Islands exempted limited partnership ("OEP VII-A LP"), One Equity Partners VII-B, L.P., a Delaware limited partnership ("OEP VII-B LP"), and OEP VII Project A Co-Investment Partners, L.P., a Delaware limited partnership ("OEP VII Project A LP" and, together with OEP VII LP, OEP VII-A LP and OEP VII-B LP, the "Parallel Funds"). The general partner of each of the Parallel Funds is OEP VII General Partner, L.P., a Cayman Islands exempted limited partnership ("OEP VII GP"), and the general partner of OEP VII GP is OEP VII GP, L.L.C., a Cayman Islands limited liability company ("OEP VII GP LLC"). OEP VII GP LLC is member-managed by Messrs. Richard Cashin and David Han.

F2 · balance_after: (Continued from Footnote 1) By virtue of the relationships described above, each of the Parallel Funds, OEP VII GP, OEP VII GP LLC and Messrs. Richard Cashin and David Han may be deemed to beneficially own, and share voting and dispositive power with respect to, the securities held directly by Investor. Each of the reporting persons disclaims beneficial ownership of the securities except to the extent of its or his pecuniary interest therein.

F3 · balance_after: In connection with a re-allocation of ownership interests in Investor, the Reporting Persons are filing this Form 4 to report the acquisition by OEP VII Project A LP of additional membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisition. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transaction.

F1 · ownership.nature: These securities are held directly by OEP AHCO Investment Holdings, LLC ("Investor"). Investor is owned by One Equity Partners VII, L.P., a Cayman Islands exempted limited partnership ("OEP VII LP"), One Equity Partners VII-A, L.P., a Cayman Islands exempted limited partnership ("OEP VII-A LP"), One Equity Partners VII-B, L.P., a Delaware limited partnership ("OEP VII-B LP"), and OEP VII Project A Co-Investment Partners, L.P., a Delaware limited partnership ("OEP VII Project A LP" and, together with OEP VII LP, OEP VII-A LP and OEP VII-B LP, the "Parallel Funds"). The general partner of each of the Parallel Funds is OEP VII General Partner, L.P., a Cayman Islands exempted limited partnership ("OEP VII GP"), and the general partner of OEP VII GP is OEP VII GP, L.L.C., a Cayman Islands limited liability company ("OEP VII GP LLC"). OEP VII GP LLC is member-managed by Messrs. Richard Cashin and David Han.

F2 · ownership.nature: (Continued from Footnote 1) By virtue of the relationships described above, each of the Parallel Funds, OEP VII GP, OEP VII GP LLC and Messrs. Richard Cashin and David Han may be deemed to beneficially own, and share voting and dispositive power with respect to, the securities held directly by Investor. Each of the reporting persons disclaims beneficial ownership of the securities except to the extent of its or his pecuniary interest therein.

SEC source: 0000899243-20-021871 · doc4.xml · nonDerivative · entry 1

OEP VII GP, L.L.C. · CIK 0001817118 · 10% owner

OEP AHCO Investment Holdings, LLC · CIK 0001817112 · 10% owner

ONE EQUITY PARTNERS VII, L.P. · CIK 0001733523 · 10% owner

ONE EQUITY PARTNERS VII-A, L.P. · CIK 0001733525 · 10% owner

ONE EQUITY PARTNERS VII-B, L.P. · CIK 0001733528 · 10% owner

OEP VII Project A Co-Investment Partners, L.P. · CIK 0001817120 · 10% owner

OEP VII General Partner, L.P. · CIK 0001817115 · 10% owner

CASHIN RICHARD M JR · CIK 0001172898 · 10% owner

Han David · CIK 0001817107 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 10,930,471

F3 · kind: In connection with a re-allocation of ownership interests in Investor, the Reporting Persons are filing this Form 4 to report the acquisition by OEP VII Project A LP of additional membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisition. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transaction.

F3 · shares: In connection with a re-allocation of ownership interests in Investor, the Reporting Persons are filing this Form 4 to report the acquisition by OEP VII Project A LP of additional membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisition. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transaction.

F3 · price: In connection with a re-allocation of ownership interests in Investor, the Reporting Persons are filing this Form 4 to report the acquisition by OEP VII Project A LP of additional membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisition. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transaction.

F3 · acquired: In connection with a re-allocation of ownership interests in Investor, the Reporting Persons are filing this Form 4 to report the acquisition by OEP VII Project A LP of additional membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisition. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transaction.

F1 · balance_after: These securities are held directly by OEP AHCO Investment Holdings, LLC ("Investor"). Investor is owned by One Equity Partners VII, L.P., a Cayman Islands exempted limited partnership ("OEP VII LP"), One Equity Partners VII-A, L.P., a Cayman Islands exempted limited partnership ("OEP VII-A LP"), One Equity Partners VII-B, L.P., a Delaware limited partnership ("OEP VII-B LP"), and OEP VII Project A Co-Investment Partners, L.P., a Delaware limited partnership ("OEP VII Project A LP" and, together with OEP VII LP, OEP VII-A LP and OEP VII-B LP, the "Parallel Funds"). The general partner of each of the Parallel Funds is OEP VII General Partner, L.P., a Cayman Islands exempted limited partnership ("OEP VII GP"), and the general partner of OEP VII GP is OEP VII GP, L.L.C., a Cayman Islands limited liability company ("OEP VII GP LLC"). OEP VII GP LLC is member-managed by Messrs. Richard Cashin and David Han.

F2 · balance_after: (Continued from Footnote 1) By virtue of the relationships described above, each of the Parallel Funds, OEP VII GP, OEP VII GP LLC and Messrs. Richard Cashin and David Han may be deemed to beneficially own, and share voting and dispositive power with respect to, the securities held directly by Investor. Each of the reporting persons disclaims beneficial ownership of the securities except to the extent of its or his pecuniary interest therein.

F3 · balance_after: In connection with a re-allocation of ownership interests in Investor, the Reporting Persons are filing this Form 4 to report the acquisition by OEP VII Project A LP of additional membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisition. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transaction.

F1 · ownership.nature: These securities are held directly by OEP AHCO Investment Holdings, LLC ("Investor"). Investor is owned by One Equity Partners VII, L.P., a Cayman Islands exempted limited partnership ("OEP VII LP"), One Equity Partners VII-A, L.P., a Cayman Islands exempted limited partnership ("OEP VII-A LP"), One Equity Partners VII-B, L.P., a Delaware limited partnership ("OEP VII-B LP"), and OEP VII Project A Co-Investment Partners, L.P., a Delaware limited partnership ("OEP VII Project A LP" and, together with OEP VII LP, OEP VII-A LP and OEP VII-B LP, the "Parallel Funds"). The general partner of each of the Parallel Funds is OEP VII General Partner, L.P., a Cayman Islands exempted limited partnership ("OEP VII GP"), and the general partner of OEP VII GP is OEP VII GP, L.L.C., a Cayman Islands limited liability company ("OEP VII GP LLC"). OEP VII GP LLC is member-managed by Messrs. Richard Cashin and David Han.

F2 · ownership.nature: (Continued from Footnote 1) By virtue of the relationships described above, each of the Parallel Funds, OEP VII GP, OEP VII GP LLC and Messrs. Richard Cashin and David Han may be deemed to beneficially own, and share voting and dispositive power with respect to, the securities held directly by Investor. Each of the reporting persons disclaims beneficial ownership of the securities except to the extent of its or his pecuniary interest therein.

SEC source: 0000899243-20-018844 · doc4.xml · derivative · entry 4

OEP VII GP, L.L.C. · CIK 0001817118 · 10% owner

OEP AHCO Investment Holdings, LLC · CIK 0001817112 · 10% owner

ONE EQUITY PARTNERS VII, L.P. · CIK 0001733523 · 10% owner

ONE EQUITY PARTNERS VII-A, L.P. · CIK 0001733525 · 10% owner

ONE EQUITY PARTNERS VII-B, L.P. · CIK 0001733528 · 10% owner

OEP VII Project A Co-Investment Partners, L.P. · CIK 0001817120 · 10% owner

OEP VII General Partner, L.P. · CIK 0001817115 · 10% owner

CASHIN RICHARD M JR · CIK 0001172898 · 10% owner

Han David · CIK 0001817107 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 39,706

Underlying: Class A Common Stock · 455,940 shares

Expires not disclosed

F4 · derivative.exercise_price: The number of shares of Class A Common Stock of AdaptHealth Corp., a Delaware corporation (the "Issuer"), having par value of $0.0001 per share (the "Class A Common Stock"), deliverable upon conversion of each share of Series A Convertible Preferred Stock, par value $0.0001 per share (the "Series A Preferred Stock"), is equal to 72.727273 shares, subject to customary anti-dilution and other adjustments. The terms of the Series A Preferred Stock generally restrict the conversion of such shares until the shares of Class A Common Stock issuable upon conversion thereof has been approved by stockholders of the Issuer in accordance with Nasdaq Listing Rules. Thereafter, the holder or the Issuer may convert the Series A Preferred Stock. The Series A Preferred Stock has no expiration date.

F3 · kind: In connection with a re-allocation of ownership interests in Investor, the Reporting Persons are filing this Form 4 to report the acquisition by OEP VII Project A LP of membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisition. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transaction.

F3 · shares: In connection with a re-allocation of ownership interests in Investor, the Reporting Persons are filing this Form 4 to report the acquisition by OEP VII Project A LP of membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisition. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transaction.

F3 · price: In connection with a re-allocation of ownership interests in Investor, the Reporting Persons are filing this Form 4 to report the acquisition by OEP VII Project A LP of membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisition. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transaction.

F4 · price: The number of shares of Class A Common Stock of AdaptHealth Corp., a Delaware corporation (the "Issuer"), having par value of $0.0001 per share (the "Class A Common Stock"), deliverable upon conversion of each share of Series A Convertible Preferred Stock, par value $0.0001 per share (the "Series A Preferred Stock"), is equal to 72.727273 shares, subject to customary anti-dilution and other adjustments. The terms of the Series A Preferred Stock generally restrict the conversion of such shares until the shares of Class A Common Stock issuable upon conversion thereof has been approved by stockholders of the Issuer in accordance with Nasdaq Listing Rules. Thereafter, the holder or the Issuer may convert the Series A Preferred Stock. The Series A Preferred Stock has no expiration date.

F4 · derivative.exercise_date: The number of shares of Class A Common Stock of AdaptHealth Corp., a Delaware corporation (the "Issuer"), having par value of $0.0001 per share (the "Class A Common Stock"), deliverable upon conversion of each share of Series A Convertible Preferred Stock, par value $0.0001 per share (the "Series A Preferred Stock"), is equal to 72.727273 shares, subject to customary anti-dilution and other adjustments. The terms of the Series A Preferred Stock generally restrict the conversion of such shares until the shares of Class A Common Stock issuable upon conversion thereof has been approved by stockholders of the Issuer in accordance with Nasdaq Listing Rules. Thereafter, the holder or the Issuer may convert the Series A Preferred Stock. The Series A Preferred Stock has no expiration date.

F4 · derivative.expiration_date: The number of shares of Class A Common Stock of AdaptHealth Corp., a Delaware corporation (the "Issuer"), having par value of $0.0001 per share (the "Class A Common Stock"), deliverable upon conversion of each share of Series A Convertible Preferred Stock, par value $0.0001 per share (the "Series A Preferred Stock"), is equal to 72.727273 shares, subject to customary anti-dilution and other adjustments. The terms of the Series A Preferred Stock generally restrict the conversion of such shares until the shares of Class A Common Stock issuable upon conversion thereof has been approved by stockholders of the Issuer in accordance with Nasdaq Listing Rules. Thereafter, the holder or the Issuer may convert the Series A Preferred Stock. The Series A Preferred Stock has no expiration date.

F3 · derivative.underlying_shares: In connection with a re-allocation of ownership interests in Investor, the Reporting Persons are filing this Form 4 to report the acquisition by OEP VII Project A LP of membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisition. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transaction.

F4 · derivative.underlying_shares: The number of shares of Class A Common Stock of AdaptHealth Corp., a Delaware corporation (the "Issuer"), having par value of $0.0001 per share (the "Class A Common Stock"), deliverable upon conversion of each share of Series A Convertible Preferred Stock, par value $0.0001 per share (the "Series A Preferred Stock"), is equal to 72.727273 shares, subject to customary anti-dilution and other adjustments. The terms of the Series A Preferred Stock generally restrict the conversion of such shares until the shares of Class A Common Stock issuable upon conversion thereof has been approved by stockholders of the Issuer in accordance with Nasdaq Listing Rules. Thereafter, the holder or the Issuer may convert the Series A Preferred Stock. The Series A Preferred Stock has no expiration date.

F3 · balance_after: In connection with a re-allocation of ownership interests in Investor, the Reporting Persons are filing this Form 4 to report the acquisition by OEP VII Project A LP of membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisition. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transaction.

F4 · balance_after: The number of shares of Class A Common Stock of AdaptHealth Corp., a Delaware corporation (the "Issuer"), having par value of $0.0001 per share (the "Class A Common Stock"), deliverable upon conversion of each share of Series A Convertible Preferred Stock, par value $0.0001 per share (the "Series A Preferred Stock"), is equal to 72.727273 shares, subject to customary anti-dilution and other adjustments. The terms of the Series A Preferred Stock generally restrict the conversion of such shares until the shares of Class A Common Stock issuable upon conversion thereof has been approved by stockholders of the Issuer in accordance with Nasdaq Listing Rules. Thereafter, the holder or the Issuer may convert the Series A Preferred Stock. The Series A Preferred Stock has no expiration date.

F1 · ownership.nature: These securities are held directly by OEP AHCO Investment Holdings, LLC ("Investor"). Investor is owned by One Equity Partners VII, L.P., a Cayman Islands exempted limited partnership ("OEP VII LP"), One Equity Partners VII-A, L.P., a Cayman Islands exempted limited partnership ("OEP VII-A LP"), One Equity Partners VII-B, L.P., a Delaware limited partnership ("OEP VII-B LP"), and OEP VII Project A Co-Investment Partners, L.P., a Delaware limited partnership ("OEP VII Project A LP" and, together with OEP VII LP, OEP VII-A LP and OEP VII-B LP, the "Parallel Funds"). The general partner of each of the Parallel Funds is OEP VII General Partner, L.P., a Cayman Islands exempted limited partnership ("OEP VII GP"), and the general partner of OEP VII GP is OEP VII GP, L.L.C., a Cayman Islands limited liability company ("OEP VII GP LLC"). OEP VII GP LLC is member-managed by Messrs. Richard Cashin and David Han.

F2 · ownership.nature: (Continued from Footnote 1) By virtue of the relationships described above, each of the Parallel Funds, OEP VII GP, OEP VII GP LLC and Messrs. Richard Cashin and David Han may be deemed to beneficially own, and share voting and dispositive power with respect to, the securities held directly by Investor. Each of the reporting persons disclaims beneficial ownership of the securities except to the extent of its or his pecuniary interest therein.

SEC source: 0000899243-20-018844 · doc4.xml · derivative · entry 3

OEP VII GP, L.L.C. · CIK 0001817118 · 10% owner

OEP AHCO Investment Holdings, LLC · CIK 0001817112 · 10% owner

ONE EQUITY PARTNERS VII, L.P. · CIK 0001733523 · 10% owner

ONE EQUITY PARTNERS VII-A, L.P. · CIK 0001733525 · 10% owner

ONE EQUITY PARTNERS VII-B, L.P. · CIK 0001733528 · 10% owner

OEP VII Project A Co-Investment Partners, L.P. · CIK 0001817120 · 10% owner

OEP VII General Partner, L.P. · CIK 0001817115 · 10% owner

CASHIN RICHARD M JR · CIK 0001172898 · 10% owner

Han David · CIK 0001817107 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 39,706

Underlying: Class A Common Stock · 455,940 shares

Expires not disclosed

F4 · derivative.exercise_price: The number of shares of Class A Common Stock of AdaptHealth Corp., a Delaware corporation (the "Issuer"), having par value of $0.0001 per share (the "Class A Common Stock"), deliverable upon conversion of each share of Series A Convertible Preferred Stock, par value $0.0001 per share (the "Series A Preferred Stock"), is equal to 72.727273 shares, subject to customary anti-dilution and other adjustments. The terms of the Series A Preferred Stock generally restrict the conversion of such shares until the shares of Class A Common Stock issuable upon conversion thereof has been approved by stockholders of the Issuer in accordance with Nasdaq Listing Rules. Thereafter, the holder or the Issuer may convert the Series A Preferred Stock. The Series A Preferred Stock has no expiration date.

F3 · kind: In connection with a re-allocation of ownership interests in Investor, the Reporting Persons are filing this Form 4 to report the acquisition by OEP VII Project A LP of membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisition. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transaction.

F3 · shares: In connection with a re-allocation of ownership interests in Investor, the Reporting Persons are filing this Form 4 to report the acquisition by OEP VII Project A LP of membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisition. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transaction.

F3 · price: In connection with a re-allocation of ownership interests in Investor, the Reporting Persons are filing this Form 4 to report the acquisition by OEP VII Project A LP of membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisition. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transaction.

F4 · price: The number of shares of Class A Common Stock of AdaptHealth Corp., a Delaware corporation (the "Issuer"), having par value of $0.0001 per share (the "Class A Common Stock"), deliverable upon conversion of each share of Series A Convertible Preferred Stock, par value $0.0001 per share (the "Series A Preferred Stock"), is equal to 72.727273 shares, subject to customary anti-dilution and other adjustments. The terms of the Series A Preferred Stock generally restrict the conversion of such shares until the shares of Class A Common Stock issuable upon conversion thereof has been approved by stockholders of the Issuer in accordance with Nasdaq Listing Rules. Thereafter, the holder or the Issuer may convert the Series A Preferred Stock. The Series A Preferred Stock has no expiration date.

F4 · derivative.exercise_date: The number of shares of Class A Common Stock of AdaptHealth Corp., a Delaware corporation (the "Issuer"), having par value of $0.0001 per share (the "Class A Common Stock"), deliverable upon conversion of each share of Series A Convertible Preferred Stock, par value $0.0001 per share (the "Series A Preferred Stock"), is equal to 72.727273 shares, subject to customary anti-dilution and other adjustments. The terms of the Series A Preferred Stock generally restrict the conversion of such shares until the shares of Class A Common Stock issuable upon conversion thereof has been approved by stockholders of the Issuer in accordance with Nasdaq Listing Rules. Thereafter, the holder or the Issuer may convert the Series A Preferred Stock. The Series A Preferred Stock has no expiration date.

F4 · derivative.expiration_date: The number of shares of Class A Common Stock of AdaptHealth Corp., a Delaware corporation (the "Issuer"), having par value of $0.0001 per share (the "Class A Common Stock"), deliverable upon conversion of each share of Series A Convertible Preferred Stock, par value $0.0001 per share (the "Series A Preferred Stock"), is equal to 72.727273 shares, subject to customary anti-dilution and other adjustments. The terms of the Series A Preferred Stock generally restrict the conversion of such shares until the shares of Class A Common Stock issuable upon conversion thereof has been approved by stockholders of the Issuer in accordance with Nasdaq Listing Rules. Thereafter, the holder or the Issuer may convert the Series A Preferred Stock. The Series A Preferred Stock has no expiration date.

F3 · derivative.underlying_shares: In connection with a re-allocation of ownership interests in Investor, the Reporting Persons are filing this Form 4 to report the acquisition by OEP VII Project A LP of membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisition. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transaction.

F4 · derivative.underlying_shares: The number of shares of Class A Common Stock of AdaptHealth Corp., a Delaware corporation (the "Issuer"), having par value of $0.0001 per share (the "Class A Common Stock"), deliverable upon conversion of each share of Series A Convertible Preferred Stock, par value $0.0001 per share (the "Series A Preferred Stock"), is equal to 72.727273 shares, subject to customary anti-dilution and other adjustments. The terms of the Series A Preferred Stock generally restrict the conversion of such shares until the shares of Class A Common Stock issuable upon conversion thereof has been approved by stockholders of the Issuer in accordance with Nasdaq Listing Rules. Thereafter, the holder or the Issuer may convert the Series A Preferred Stock. The Series A Preferred Stock has no expiration date.

F3 · balance_after: In connection with a re-allocation of ownership interests in Investor, the Reporting Persons are filing this Form 4 to report the acquisition by OEP VII Project A LP of membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisition. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transaction.

F4 · balance_after: The number of shares of Class A Common Stock of AdaptHealth Corp., a Delaware corporation (the "Issuer"), having par value of $0.0001 per share (the "Class A Common Stock"), deliverable upon conversion of each share of Series A Convertible Preferred Stock, par value $0.0001 per share (the "Series A Preferred Stock"), is equal to 72.727273 shares, subject to customary anti-dilution and other adjustments. The terms of the Series A Preferred Stock generally restrict the conversion of such shares until the shares of Class A Common Stock issuable upon conversion thereof has been approved by stockholders of the Issuer in accordance with Nasdaq Listing Rules. Thereafter, the holder or the Issuer may convert the Series A Preferred Stock. The Series A Preferred Stock has no expiration date.

F1 · ownership.nature: These securities are held directly by OEP AHCO Investment Holdings, LLC ("Investor"). Investor is owned by One Equity Partners VII, L.P., a Cayman Islands exempted limited partnership ("OEP VII LP"), One Equity Partners VII-A, L.P., a Cayman Islands exempted limited partnership ("OEP VII-A LP"), One Equity Partners VII-B, L.P., a Delaware limited partnership ("OEP VII-B LP"), and OEP VII Project A Co-Investment Partners, L.P., a Delaware limited partnership ("OEP VII Project A LP" and, together with OEP VII LP, OEP VII-A LP and OEP VII-B LP, the "Parallel Funds"). The general partner of each of the Parallel Funds is OEP VII General Partner, L.P., a Cayman Islands exempted limited partnership ("OEP VII GP"), and the general partner of OEP VII GP is OEP VII GP, L.L.C., a Cayman Islands limited liability company ("OEP VII GP LLC"). OEP VII GP LLC is member-managed by Messrs. Richard Cashin and David Han.

F2 · ownership.nature: (Continued from Footnote 1) By virtue of the relationships described above, each of the Parallel Funds, OEP VII GP, OEP VII GP LLC and Messrs. Richard Cashin and David Han may be deemed to beneficially own, and share voting and dispositive power with respect to, the securities held directly by Investor. Each of the reporting persons disclaims beneficial ownership of the securities except to the extent of its or his pecuniary interest therein.

SEC source: 0000899243-20-018844 · doc4.xml · nonDerivative · entry 2

OEP VII GP, L.L.C. · CIK 0001817118 · 10% owner

OEP AHCO Investment Holdings, LLC · CIK 0001817112 · 10% owner

ONE EQUITY PARTNERS VII, L.P. · CIK 0001733523 · 10% owner

ONE EQUITY PARTNERS VII-A, L.P. · CIK 0001733525 · 10% owner

ONE EQUITY PARTNERS VII-B, L.P. · CIK 0001733528 · 10% owner

OEP VII Project A Co-Investment Partners, L.P. · CIK 0001817120 · 10% owner

OEP VII General Partner, L.P. · CIK 0001817115 · 10% owner

CASHIN RICHARD M JR · CIK 0001172898 · 10% owner

Han David · CIK 0001817107 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 10,930,471

F3 · kind: In connection with a re-allocation of ownership interests in Investor, the Reporting Persons are filing this Form 4 to report the acquisition by OEP VII Project A LP of membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisition. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transaction.

F3 · shares: In connection with a re-allocation of ownership interests in Investor, the Reporting Persons are filing this Form 4 to report the acquisition by OEP VII Project A LP of membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisition. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transaction.

F3 · price: In connection with a re-allocation of ownership interests in Investor, the Reporting Persons are filing this Form 4 to report the acquisition by OEP VII Project A LP of membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisition. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transaction.

F3 · acquired: In connection with a re-allocation of ownership interests in Investor, the Reporting Persons are filing this Form 4 to report the acquisition by OEP VII Project A LP of membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisition. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transaction.

F1 · balance_after: These securities are held directly by OEP AHCO Investment Holdings, LLC ("Investor"). Investor is owned by One Equity Partners VII, L.P., a Cayman Islands exempted limited partnership ("OEP VII LP"), One Equity Partners VII-A, L.P., a Cayman Islands exempted limited partnership ("OEP VII-A LP"), One Equity Partners VII-B, L.P., a Delaware limited partnership ("OEP VII-B LP"), and OEP VII Project A Co-Investment Partners, L.P., a Delaware limited partnership ("OEP VII Project A LP" and, together with OEP VII LP, OEP VII-A LP and OEP VII-B LP, the "Parallel Funds"). The general partner of each of the Parallel Funds is OEP VII General Partner, L.P., a Cayman Islands exempted limited partnership ("OEP VII GP"), and the general partner of OEP VII GP is OEP VII GP, L.L.C., a Cayman Islands limited liability company ("OEP VII GP LLC"). OEP VII GP LLC is member-managed by Messrs. Richard Cashin and David Han.

F2 · balance_after: (Continued from Footnote 1) By virtue of the relationships described above, each of the Parallel Funds, OEP VII GP, OEP VII GP LLC and Messrs. Richard Cashin and David Han may be deemed to beneficially own, and share voting and dispositive power with respect to, the securities held directly by Investor. Each of the reporting persons disclaims beneficial ownership of the securities except to the extent of its or his pecuniary interest therein.

F3 · balance_after: In connection with a re-allocation of ownership interests in Investor, the Reporting Persons are filing this Form 4 to report the acquisition by OEP VII Project A LP of membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisition. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transaction.

F1 · ownership.nature: These securities are held directly by OEP AHCO Investment Holdings, LLC ("Investor"). Investor is owned by One Equity Partners VII, L.P., a Cayman Islands exempted limited partnership ("OEP VII LP"), One Equity Partners VII-A, L.P., a Cayman Islands exempted limited partnership ("OEP VII-A LP"), One Equity Partners VII-B, L.P., a Delaware limited partnership ("OEP VII-B LP"), and OEP VII Project A Co-Investment Partners, L.P., a Delaware limited partnership ("OEP VII Project A LP" and, together with OEP VII LP, OEP VII-A LP and OEP VII-B LP, the "Parallel Funds"). The general partner of each of the Parallel Funds is OEP VII General Partner, L.P., a Cayman Islands exempted limited partnership ("OEP VII GP"), and the general partner of OEP VII GP is OEP VII GP, L.L.C., a Cayman Islands limited liability company ("OEP VII GP LLC"). OEP VII GP LLC is member-managed by Messrs. Richard Cashin and David Han.

F2 · ownership.nature: (Continued from Footnote 1) By virtue of the relationships described above, each of the Parallel Funds, OEP VII GP, OEP VII GP LLC and Messrs. Richard Cashin and David Han may be deemed to beneficially own, and share voting and dispositive power with respect to, the securities held directly by Investor. Each of the reporting persons disclaims beneficial ownership of the securities except to the extent of its or his pecuniary interest therein.

SEC source: 0000899243-20-018844 · doc4.xml · nonDerivative · entry 1

OEP VII GP, L.L.C. · CIK 0001817118 · 10% owner

OEP AHCO Investment Holdings, LLC · CIK 0001817112 · 10% owner

ONE EQUITY PARTNERS VII, L.P. · CIK 0001733523 · 10% owner

ONE EQUITY PARTNERS VII-A, L.P. · CIK 0001733525 · 10% owner

ONE EQUITY PARTNERS VII-B, L.P. · CIK 0001733528 · 10% owner

OEP VII Project A Co-Investment Partners, L.P. · CIK 0001817120 · 10% owner

OEP VII General Partner, L.P. · CIK 0001817115 · 10% owner

CASHIN RICHARD M JR · CIK 0001172898 · 10% owner

Han David · CIK 0001817107 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 10,930,471

F3 · kind: In connection with a re-allocation of ownership interests in Investor, the Reporting Persons are filing this Form 4 to report the acquisition by OEP VII Project A LP of membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisition. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transaction.

F3 · shares: In connection with a re-allocation of ownership interests in Investor, the Reporting Persons are filing this Form 4 to report the acquisition by OEP VII Project A LP of membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisition. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transaction.

F3 · price: In connection with a re-allocation of ownership interests in Investor, the Reporting Persons are filing this Form 4 to report the acquisition by OEP VII Project A LP of membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisition. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transaction.

F3 · acquired: In connection with a re-allocation of ownership interests in Investor, the Reporting Persons are filing this Form 4 to report the acquisition by OEP VII Project A LP of membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisition. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transaction.

F1 · balance_after: These securities are held directly by OEP AHCO Investment Holdings, LLC ("Investor"). Investor is owned by One Equity Partners VII, L.P., a Cayman Islands exempted limited partnership ("OEP VII LP"), One Equity Partners VII-A, L.P., a Cayman Islands exempted limited partnership ("OEP VII-A LP"), One Equity Partners VII-B, L.P., a Delaware limited partnership ("OEP VII-B LP"), and OEP VII Project A Co-Investment Partners, L.P., a Delaware limited partnership ("OEP VII Project A LP" and, together with OEP VII LP, OEP VII-A LP and OEP VII-B LP, the "Parallel Funds"). The general partner of each of the Parallel Funds is OEP VII General Partner, L.P., a Cayman Islands exempted limited partnership ("OEP VII GP"), and the general partner of OEP VII GP is OEP VII GP, L.L.C., a Cayman Islands limited liability company ("OEP VII GP LLC"). OEP VII GP LLC is member-managed by Messrs. Richard Cashin and David Han.

F2 · balance_after: (Continued from Footnote 1) By virtue of the relationships described above, each of the Parallel Funds, OEP VII GP, OEP VII GP LLC and Messrs. Richard Cashin and David Han may be deemed to beneficially own, and share voting and dispositive power with respect to, the securities held directly by Investor. Each of the reporting persons disclaims beneficial ownership of the securities except to the extent of its or his pecuniary interest therein.

F3 · balance_after: In connection with a re-allocation of ownership interests in Investor, the Reporting Persons are filing this Form 4 to report the acquisition by OEP VII Project A LP of membership interests in Investor, which reduced the relative percentage of membership interests of Investor owned by each of OEP VII LP, OEP VII-A LP and OEP VII-B LP prior to such acquisition. No shares of Class A Common Stock or Series A Convertible Preferred Stock were transferred by Investor in connection with such transaction.

F1 · ownership.nature: These securities are held directly by OEP AHCO Investment Holdings, LLC ("Investor"). Investor is owned by One Equity Partners VII, L.P., a Cayman Islands exempted limited partnership ("OEP VII LP"), One Equity Partners VII-A, L.P., a Cayman Islands exempted limited partnership ("OEP VII-A LP"), One Equity Partners VII-B, L.P., a Delaware limited partnership ("OEP VII-B LP"), and OEP VII Project A Co-Investment Partners, L.P., a Delaware limited partnership ("OEP VII Project A LP" and, together with OEP VII LP, OEP VII-A LP and OEP VII-B LP, the "Parallel Funds"). The general partner of each of the Parallel Funds is OEP VII General Partner, L.P., a Cayman Islands exempted limited partnership ("OEP VII GP"), and the general partner of OEP VII GP is OEP VII GP, L.L.C., a Cayman Islands limited liability company ("OEP VII GP LLC"). OEP VII GP LLC is member-managed by Messrs. Richard Cashin and David Han.

F2 · ownership.nature: (Continued from Footnote 1) By virtue of the relationships described above, each of the Parallel Funds, OEP VII GP, OEP VII GP LLC and Messrs. Richard Cashin and David Han may be deemed to beneficially own, and share voting and dispositive power with respect to, the securities held directly by Investor. Each of the reporting persons disclaims beneficial ownership of the securities except to the extent of its or his pecuniary interest therein.

SEC source: 0000899243-20-014319 · doc4.xml · derivative · entry 2

BlueMountain Capital Management, LLC · CIK 0001427430 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Footnotes

Disclosed balance after: 1,898,967

Underlying: Class A and B Common Stock · 1,898,967 shares

Expires 2020-10-31

F1 · security: The filing of this Form 4 shall not be construed as an admission that BlueMountain Capital Management, LLC ("BMCM") is or was for the purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise the beneficial owner of any put options ("Put Options") relating to shares of Class A Common Stock, par value $0.0001 per share "Class A Common Stock") and Class B Common Stock, par value $0.0001 per share ("Class B Common Stock"), of AdaptHealth Corp. (the "Issuer"). Pursuant to Rule 16a-1(a)(4) of the Exchange Act, BMCM disclaims such beneficial ownership, except to the extent of its pecuniary interest.

F2 · security: BMCM is the investment manager of each of: (i) BMSB L.P. ("BMSB"); (ii) BlueMountain Fursan Fund L.P. ("FRSN"); (iii) BlueMountain Foinaven Master Fund L.P. ("BMFV"); and (iv) BlueMountain Summit Opportunities Fund II (US) L.P. (together with BMSB, FRSN and BMFV, the "Funds"), which collectively are the direct beneficial owners of 1,898,967 Put Options. BMCM, although it directs the exercise of the Put Options held by the Funds, only receives an asset-based fee relating to the Put Options held by the Funds.

F3 · security: Pursuant to the Put/Call Option and Consent Agreement (the "Option Agreement") dated as of May 25, 2020 by and between the Issuer, the Funds and the other parties thereto, the Put Options may be exercised by the Funds at a per option price equal to the greater of (x) $14.50 and (y) 85% of the current market value of a share of Class A Common Stock on the date the Put Options are exercised, as determined in accordance with the terms of the Option Agreement.

F4 · security: Pursuant to the Option Agreement, both of the Put Options and the call options issued by the Funds to the Issuer with respect to the Class A Common Stock and Class B Common Stock of the Issuer (the "Call Options") will become exercisable upon the closing date of a merger involving the Issuer, certain subsidiaries thereof, Solara Holdings, LLC and certain entities related thereto.

F5 · security: Pursuant to the Option Agreement, the Put Options and Call Options each relate to the shares of Class A Common Stock and Class B Common Stock held by the Funds, without distinguishing between such shares.

F4 · derivative.exercise_date: Pursuant to the Option Agreement, both of the Put Options and the call options issued by the Funds to the Issuer with respect to the Class A Common Stock and Class B Common Stock of the Issuer (the "Call Options") will become exercisable upon the closing date of a merger involving the Issuer, certain subsidiaries thereof, Solara Holdings, LLC and certain entities related thereto.

F5 · derivative.underlying: Pursuant to the Option Agreement, the Put Options and Call Options each relate to the shares of Class A Common Stock and Class B Common Stock held by the Funds, without distinguishing between such shares.

F1 · ownership.nature: The filing of this Form 4 shall not be construed as an admission that BlueMountain Capital Management, LLC ("BMCM") is or was for the purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise the beneficial owner of any put options ("Put Options") relating to shares of Class A Common Stock, par value $0.0001 per share "Class A Common Stock") and Class B Common Stock, par value $0.0001 per share ("Class B Common Stock"), of AdaptHealth Corp. (the "Issuer"). Pursuant to Rule 16a-1(a)(4) of the Exchange Act, BMCM disclaims such beneficial ownership, except to the extent of its pecuniary interest.

F2 · ownership.nature: BMCM is the investment manager of each of: (i) BMSB L.P. ("BMSB"); (ii) BlueMountain Fursan Fund L.P. ("FRSN"); (iii) BlueMountain Foinaven Master Fund L.P. ("BMFV"); and (iv) BlueMountain Summit Opportunities Fund II (US) L.P. (together with BMSB, FRSN and BMFV, the "Funds"), which collectively are the direct beneficial owners of 1,898,967 Put Options. BMCM, although it directs the exercise of the Put Options held by the Funds, only receives an asset-based fee relating to the Put Options held by the Funds.

SEC source: 0000899243-20-014319 · doc4.xml · derivative · entry 1

BlueMountain Capital Management, LLC · CIK 0001427430 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Footnotes

Disclosed balance after: 1,898,967

Underlying: Class A and B Common Stock · 1,898,967 shares

Expires 2020-10-31

F1 · security: The filing of this Form 4 shall not be construed as an admission that BlueMountain Capital Management, LLC ("BMCM") is or was for the purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise the beneficial owner of any put options ("Put Options") relating to shares of Class A Common Stock, par value $0.0001 per share "Class A Common Stock") and Class B Common Stock, par value $0.0001 per share ("Class B Common Stock"), of AdaptHealth Corp. (the "Issuer"). Pursuant to Rule 16a-1(a)(4) of the Exchange Act, BMCM disclaims such beneficial ownership, except to the extent of its pecuniary interest.

F2 · security: BMCM is the investment manager of each of: (i) BMSB L.P. ("BMSB"); (ii) BlueMountain Fursan Fund L.P. ("FRSN"); (iii) BlueMountain Foinaven Master Fund L.P. ("BMFV"); and (iv) BlueMountain Summit Opportunities Fund II (US) L.P. (together with BMSB, FRSN and BMFV, the "Funds"), which collectively are the direct beneficial owners of 1,898,967 Put Options. BMCM, although it directs the exercise of the Put Options held by the Funds, only receives an asset-based fee relating to the Put Options held by the Funds.

F3 · security: Pursuant to the Put/Call Option and Consent Agreement (the "Option Agreement") dated as of May 25, 2020 by and between the Issuer, the Funds and the other parties thereto, the Put Options may be exercised by the Funds at a per option price equal to the greater of (x) $14.50 and (y) 85% of the current market value of a share of Class A Common Stock on the date the Put Options are exercised, as determined in accordance with the terms of the Option Agreement.

F4 · security: Pursuant to the Option Agreement, both of the Put Options and the call options issued by the Funds to the Issuer with respect to the Class A Common Stock and Class B Common Stock of the Issuer (the "Call Options") will become exercisable upon the closing date of a merger involving the Issuer, certain subsidiaries thereof, Solara Holdings, LLC and certain entities related thereto.

F5 · security: Pursuant to the Option Agreement, the Put Options and Call Options each relate to the shares of Class A Common Stock and Class B Common Stock held by the Funds, without distinguishing between such shares.

F3 · derivative.exercise_price: Pursuant to the Put/Call Option and Consent Agreement (the "Option Agreement") dated as of May 25, 2020 by and between the Issuer, the Funds and the other parties thereto, the Put Options may be exercised by the Funds at a per option price equal to the greater of (x) $14.50 and (y) 85% of the current market value of a share of Class A Common Stock on the date the Put Options are exercised, as determined in accordance with the terms of the Option Agreement.

F4 · derivative.exercise_date: Pursuant to the Option Agreement, both of the Put Options and the call options issued by the Funds to the Issuer with respect to the Class A Common Stock and Class B Common Stock of the Issuer (the "Call Options") will become exercisable upon the closing date of a merger involving the Issuer, certain subsidiaries thereof, Solara Holdings, LLC and certain entities related thereto.

F5 · derivative.underlying: Pursuant to the Option Agreement, the Put Options and Call Options each relate to the shares of Class A Common Stock and Class B Common Stock held by the Funds, without distinguishing between such shares.

F1 · ownership.nature: The filing of this Form 4 shall not be construed as an admission that BlueMountain Capital Management, LLC ("BMCM") is or was for the purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise the beneficial owner of any put options ("Put Options") relating to shares of Class A Common Stock, par value $0.0001 per share "Class A Common Stock") and Class B Common Stock, par value $0.0001 per share ("Class B Common Stock"), of AdaptHealth Corp. (the "Issuer"). Pursuant to Rule 16a-1(a)(4) of the Exchange Act, BMCM disclaims such beneficial ownership, except to the extent of its pecuniary interest.

F2 · ownership.nature: BMCM is the investment manager of each of: (i) BMSB L.P. ("BMSB"); (ii) BlueMountain Fursan Fund L.P. ("FRSN"); (iii) BlueMountain Foinaven Master Fund L.P. ("BMFV"); and (iv) BlueMountain Summit Opportunities Fund II (US) L.P. (together with BMSB, FRSN and BMFV, the "Funds"), which collectively are the direct beneficial owners of 1,898,967 Put Options. BMCM, although it directs the exercise of the Put Options held by the Funds, only receives an asset-based fee relating to the Put Options held by the Funds.

SEC source: 0001104659-20-133875 · tm2038090-2_4seq1.xml · derivative · entry 6

McGee Luke · CIK 0001792721 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 1,823,964

Underlying: Class A Common Stock · 100,000 shares

Expires not disclosed

F7 · derivative.exercise_price: The Class B Common Stock is exchangeable (together with the same number of common units of AdaptHealth Holdings LLC) for shares of Class A Common Stock of the Issuer (or the cash value thereof). 319,724 of the common units of AdaptHealth Holdings LLC held directly by 2321 Capital LLC are subject to vesting, with 79,931 units vesting on each of the first four anniversaries of May 20, 2019.

F7 · derivative.exercise_date: The Class B Common Stock is exchangeable (together with the same number of common units of AdaptHealth Holdings LLC) for shares of Class A Common Stock of the Issuer (or the cash value thereof). 319,724 of the common units of AdaptHealth Holdings LLC held directly by 2321 Capital LLC are subject to vesting, with 79,931 units vesting on each of the first four anniversaries of May 20, 2019.

F7 · derivative.expiration_date: The Class B Common Stock is exchangeable (together with the same number of common units of AdaptHealth Holdings LLC) for shares of Class A Common Stock of the Issuer (or the cash value thereof). 319,724 of the common units of AdaptHealth Holdings LLC held directly by 2321 Capital LLC are subject to vesting, with 79,931 units vesting on each of the first four anniversaries of May 20, 2019.

F4 · ownership.nature: Securities held directly by 2321 Capital LLC.

SEC source: 0001104659-20-037406 · a4.xml · nonDerivative · entry 1

WOLF DALE B · CIK 0001228861 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,500

SEC source: 0001104659-20-029844 · a4.xml · nonDerivative · entry 1

Rietkerk Shaw · CIK 0001792695 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 107,353

SEC source: 0001104659-19-076127 · a4.xml · derivative · entry 2

Deerfield/RAB Ventures, LLC · CIK 0001731697 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,643,333 shares

Expires 2024-11-08

F1 · kind: On December 20, 2019, Deerfield/RAB Ventures, LLC (the "Sponsor"), transferred 3,672,500 shares of Class A common stock of AdaptHealth Corp. ("Adapt") and 2,643,333 warrants to purchase shares of Adapt's Class A common stock to its members in connection with the dissolution of the Sponsor, for no consideration.

F1 · price: On December 20, 2019, Deerfield/RAB Ventures, LLC (the "Sponsor"), transferred 3,672,500 shares of Class A common stock of AdaptHealth Corp. ("Adapt") and 2,643,333 warrants to purchase shares of Adapt's Class A common stock to its members in connection with the dissolution of the Sponsor, for no consideration.

SEC source: 0001104659-19-076127 · a4.xml · nonDerivative · entry 1

Deerfield/RAB Ventures, LLC · CIK 0001731697 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: On December 20, 2019, Deerfield/RAB Ventures, LLC (the "Sponsor"), transferred 3,672,500 shares of Class A common stock of AdaptHealth Corp. ("Adapt") and 2,643,333 warrants to purchase shares of Adapt's Class A common stock to its members in connection with the dissolution of the Sponsor, for no consideration.

F1 · price: On December 20, 2019, Deerfield/RAB Ventures, LLC (the "Sponsor"), transferred 3,672,500 shares of Class A common stock of AdaptHealth Corp. ("Adapt") and 2,643,333 warrants to purchase shares of Adapt's Class A common stock to its members in connection with the dissolution of the Sponsor, for no consideration.

SEC source: 0001104659-19-075225 · a4.xml · nonDerivative · entry 1

WOLF DALE B · CIK 0001228861 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

F1 · price: This transaction was executed in multiple trades at prices ranging from $10.15 to $10.20. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001104659-19-073988 · a4.xml · nonDerivative · entry 1

JOYCE CHRISTOPHER J · CIK 0001032563 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,679

SEC source: 0001104659-19-073993 · a4.xml · nonDerivative · entry 1

QUASHA ALAN G · CIK 0000921100 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,250

SEC source: 0001104659-19-073987 · a4.xml · nonDerivative · entry 1

BARASCH RICHARD A · CIK 0001076341 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,000